

INDEX

- Absorption pharmacokinetics
 - nicotine dependence and withdrawal, 543–544
- ABT431 compound
 - schizophrenia dopamine hypothesis, 373
- N*-Acetyl aspartate (NAA)
 - glutamate theory of schizophrenia
 - pathological evidence, 292
 - schizophrenia analysis, 256–257
 - schizophrenia dopamine hypothesis, 289
- N*-Acetylcysteine (NAC)
 - psychostimulant abuse and
 - cystine/glutamate transporter restoration, 576
- Acoustic startle
 - mouse anxiety models
 - neurosteroid effects, 147
- Acquired immunodeficiency syndrome (AIDS)
 - opiate addiction comorbidity with, 691–694
- Acute delivery systems
 - nicotine dependence and withdrawal therapy, 547–548
- Addictive disorders. *See also* Heroin
 - addiction; specific disorders, e.g.
 - Alcohol abuse
 - diagnostic criteria, 456–457
 - endocannabinoids, 675–676
 - γ -hydroxybutyric acid (GHB) and, 635–636
 - hallucinogens and, 639–640
 - nicotine dependence and withdrawal pharmacology, 536–545
 - absorption pharmacokinetics, 543–544
 - bupropion, 549–550
 - cannabinoid antagonists, 550
 - distribution pharmacokinetics, 544
 - metabolism and elimination pharmacokinetics, 544–545
 - nicotine reinforcement neurosubstrates, 537–540
 - nicotinic acetylcholine receptors, 537
 - functional adaptations, 540–541
 - nicotinic antagonists, 548–549
 - nicotinic partial agonists, 548
 - nonnicotinic agents, 549–551
 - opioid antagonists, 550–551
 - overview, 545–546
 - pharmacokinetics, 543–545
 - public health policy and, 551–552
 - replacement medications, 546–548
 - tricyclic antidepressants, 550
 - withdrawal neurosubstrates, 541–543
 - opiate addiction
 - buprenorphine studies, 696–698
 - drug discovery survey, 699–700
 - epidemiology, 691–694
 - future research issues, 698–699
 - treatment statistics, 694–696

- pharmacotherapy
 - history of, 451–457
 - reward modulation/countermodulation and, 458–459
 - risk factors for addiction development, 457–458
- psychostimulant abuse
 - addiction therapy development, 585–586
 - chronic exposure-related neurobiology, 579–589
 - neurotransmitter/neuroendocrine systems, 580–584
 - signal transduction mechanisms and gene expression, 584–585
 - future research issues, 588–589
 - neuropharmacology, 569–579
 - γ -aminobutyric acid, 576–577
 - glutamate, 575–576
 - hypothalamic-pituitary-adrenal axis, 577–578
 - monoamines, 570–575
 - neuropeptides, 578–579
 - overview, 567–569
 - risk factors for, 455, 457–458
 - selective serotonin reuptake inhibitors
 - anxiety disorder therapy, 67–69
- Adenosine receptors
 - anxiety neurobiology and deficits in, 29–30
- A δ fibers
 - pain pathways, 711–712
- Adolescent patients
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 581–585
- Adrenergic receptors
 - antipsychotic drugs mechanisms, 426–427
 - psychostimulant abuse, 575
- Adrenocorticotropin hormone (ACTH)
 - anxiety neurobiology and, 17
 - nicotine dependence and withdrawal, 539–540
 - psychostimulant abuse, 577–578
 - chronic exposure and sensitization effects, 580–585
- Adult environmental effects
 - anxiety neurobiology, 35
- Affective flattening
 - in schizophrenia, 255–256
- Agonist agents
 - psychostimulant abuse therapy, 586–587
- AKT1 gene
 - dystrobrevin binding protein 1 (DTNBP1)
 - schizophrenia susceptibility, 348–349
- Alcohol
 - γ -hydroxybutyric acid (GHB) and, 634
 - neurosteroid effects and, 157–158
- Alcohol abuse
 - animal models
 - neuroanatomical substrates, 466–467
 - behavioral paradigms, 467–470
 - central nervous system circuitry, 470–471
 - novel substrates, 471
 - dopamine neuronal systems and substrates, 471–486
 - bed nucleus of stria terminalis, 473–475
 - dopaminergic regulation, early
 - research, 472–473
 - extracellular dopamine, 485–486
 - future research issues, 517–518
 - GABAergic interactions with, 486
 - lateral hypothalamus, 481–485
 - D₂ dopaminergic regulation, hypothesized mechanisms, 481–485
 - ventral pallidum, 476–480
 - dopaminergic regulation
 - hypothesized mechanisms, 478–480
- GABA_A benzodiazepine receptor complex, molecular biology, 487–501
 - alcohol/modulator commonalities, 487–488
 - CA1/CA3 hippocampus, 511–516
 - efficacy of β CCT/3PBD modulation, GABA_{A1,2,3,5} receptors, 499–501
 - future research issues, 517–518
 - GABA-DA interaction hypothesis, 496–498
 - ligand selectivity with GABA_{A1} subunits, 498–499
 - microinjection studies, 505–506
 - naltrexone antagonist, 507–511
 - novel CNS GABAergic substrates, 498
 - oral administration, β CCT/3PBD
 - anxiety reduction, 510–511
 - vs. naltrexone, 507–511
 - probe applications, 488–493
 - site-specific microinjection, 493–496
 - subunit selectivity vs. intrinsic efficacy, 516–517

- systemic administration, 492–493, 503–504
 - ventral pallidum, 501–502
- overview, 466
- Alcohol-preferring rats (P rat line)
 - alcohol abuse studies
 - appropriate behavioral paradigms, 467–470
 - neuroanatomical controls, 469–470
 - reinforcer-specific controls, 469
 - central nervous system circuitry in, 470–471
 - characteristics of, 467
 - novel neuroanatomical substrates, 471
- AlloTHDOC
 - plasma levels, 137–140
- Alogia
 - in schizophrenia, 255–256
- α -Amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA)
 - benzodiazepine tolerance, 101
 - glutamate theory of schizophrenia
 - history of, 290–291
 - pathological evidence, 291–292
 - pharmacological evidence, 294–295
 - schizophrenia pharmacotherapy
 - drug development for, 392
- Amino acid neurotransmission
 - anxiety disorder therapy, 72–75
 - anticonvulsants, 74–75
 - benzodiazepines, 73–74
- Amino acid residues
 - benzodiazepines
 - GABA_A receptors, 106–108
- D-Amino acid oxidase activator (DAO A)
 - schizophrenia candidate gene, 327
- D-Amino acid oxidase (DAO)
 - schizophrenia candidate gene, 327
- Amisulpiride
 - schizophrenia therapy
 - D₂/D₃ and D₄ receptor antagonism and regional specificity, 380
- "AMPAkines"
 - glutamate theory of schizophrenia, 295
- Amphetamine
 - chronic exposure and sensitization effects, 580–585
 - 3,4-methylenedioxymethamphetamine
 - reinforcement of, 615–616
 - monoamine neuropharmacology, 571–575
 - neuropeptide pharmacology and, 579
- d*-Amphetamine
 - alcohol abuse studies
 - dopaminergic receptor systems and substrates, 472–473
- Amygdala. *See also* Extended amygdala (EA)
 - anxiety disorders and, 13–15
- Anandamide
 - appetite regulation and, 671–672
 - endocannabinoid ligands, 663–664
 - pain management and, 667–668
 - pharmacology, 665–675
- Anesthesia
 - neuroactive steroid effects and, 158–159
- Animal models. *See also* Mouse studies
 - alcohol-motivated behaviors
 - neuroanatomical substrates, 466–467
 - behavioral paradigms, 467–470
 - central nervous system circuitry, 470–471
 - novel substrates, 471
 - anxiety neurobiology
 - anxiety-like behavior in, 10–12
 - brain imaging studies, 14–15
 - early-life environmental effects, 33–34
 - rodent models, 6–9
 - 3,4-methylenedioxymethamphetamine
 - neurotoxicity, 620–621
 - behavioral effects, 630–631
 - neurosteroid effects, 142–152
 - acoustic/fear-potentiated startle, 147
 - defensive burying behavior, 149–150
 - elevated-plus maze, 143–145
 - Geller/Seifter and Vogel conflict tests, 145–146
 - light-dark box, 146–147
 - mild mental stress models and social isolation, 151–152
 - mirrored chamber, 147–148
 - modified forced-swim test, 150–151
 - open-field activity, 148–149
 - separation-induced ultrasonic vocalizations, 150
 - obsessive-compulsive disorders (OCD), 224
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 581–585
 - schizophrenia, 263–265
 - transient receptor potential V1 (TRPV1) receptors, 736
- Anticonvulsants
 - anxiety disorder therapy, 74–75

- migraine management, 766–767
- Δ^9 -tetrahydrocannabinol as, 672–673
- Antidepressants
 - anxiety disorder therapy, 64–70
 - beta blockers, 71
 - mirtazapine, 70
 - monoamine oxidase inhibitors, 70
 - selective serotonin reuptake inhibitors, 66–69
 - serotonin and noradrenaline reuptake inhibitors, 69
 - serotonin receptor agonists, 70–71
 - tricyclic antidepressants, 69–70
 - migraine management, 767
 - nicotine dependence and withdrawal therapy
 - bupropion, 549–550
 - tricyclic
 - nicotine dependence and withdrawal therapy, 550
- Antiemetics
 - migraine management, 765
- Antihistamines
 - anxiety disorder therapy, 75
- Antinociception
 - cannabinoid analgesics and, 668
- Antipsychotics
 - anxiety disorder therapy, 71–72
 - atypical agents, mechanisms of action
 - adrenergic mechanisms, 426–427
 - atypical antipsychotics
 - 5-HT_{2A} receptor, 418–421
 - cholinergic mechanisms, 429–430
 - clozapine regimens
 - dopamine D₂ receptor blockade, 412–415
 - glutamatergic mechanisms, 427–429
 - neurogenesis, 430
 - neurokinin 3 receptors, 430
 - partial dopamine agonists, 416–417
 - serotonin receptor 5-HT_{1A}-5-HT_{2A} interactions, 424–425
 - serotonin receptor 5-HT_{2A}-5-HT_{2C} interactions, 422–424
 - serotonin receptor 5-HT₆, 425–426
 - serotonin receptors, 417–418
 - serotonin release, 426
 - serotonin receptor 5-HT_{2A} blockade
 - cortical dopamine efflux and cognitive function, 421–422
 - extrapyramidal function, 422
 - substituted benzamides
 - D₁, D₃, and D₄ receptors, 415–416
 - table of drugs, 413
 - typical vs. atypical drugs, 411–412
 - metabolic syndrome with, 254
 - obsessive-compulsive disorders
 - neuropharmacology, 229–234
 - symptom induction from, 234
 - schizophrenia therapy
 - first-generation (conventional) agents, 383
 - glutamate theory of schizophrenia, 294–295
 - history of, 370–371
 - hypothesized mechanisms of action, 376–382
 - D₁ receptors, 380–381
 - D₂/D₃ and D₄ antagonism and regional specificity, 380
 - D₂ occupancy thresholds and rapid dissociation, 378–380
 - D₂ receptor occupancy, 376–378
 - dopamine release, 381
 - NMDA receptor function, 381
 - synthesis reactions, 381–382
 - negative affect remediation, 255–256
 - psychosis management, 254
 - safety and tolerability, 387–388
 - second-generation (atypical) agents, 383–387
- Anxiety and anxiety disorders
 - alcohol abuse and
 - β CCT/3PBC anxiety reduction efficacy, 510–511
 - clinical management, 60–61
 - corticotropin-releasing factor receptor antagonists
 - therapeutic potential of, 196–198
 - depression and
 - pharmacotherapy, 80
 - diagnostic criteria, 9–12, 61–62
 - 3,4-methylenedioxymethamphetamine
 - effects, 630–631
 - neuroactive steroids
 - alcohol effects, 157–159
 - animal models, 142–152
 - behavioral effects, 142
 - brain and peripheral sources, 135–137
 - chemistry and pharmacology, 135–142
 - enantiomeric selectivity, 141–142
 - GABA_A receptors and ligand-gated ion channels, 137–141

- HPA axis function, 154–156
- overview, 134–135
- stress-induced behaviors, 154–155
- neurobiology of
 - basic principles, 4
 - early-life environmental effects, 33–37
 - fear/anxiety circuits, 13–15
 - genetic susceptibility, 18–19
 - intracellular regulators, 30–33
 - knockout mice
 - neuronal messenger alterations, 24–26
 - neurotransmitter receptor deficits and CRH proteins, 26–30
 - mouse genetics studies, 19–24
 - neurotransmitter systems and neuronal messengers, 15–18
 - psychological traits
 - continuous expression of normal personality, 9–10
 - genetic basis of, 4–6
 - mouse behavior extrapolation studies, 6–9
- pharmacotherapy
 - anxiolytic drugs, 62–75
 - amino acid neurotransmission, 72–75
 - anticonvulsants, 74–75
 - antidepressants, 64–70
 - antihistamines, 75
 - antipsychotics, 71–72
 - benzodiazepines, 73–74
 - beta-blockers, 71
 - lithium, 75
 - monoamine neurotransmission, 63–72
 - serotonin receptor agonists, 70–71
 - depressive disorders, 80
 - future research issues, 81
 - generalized anxiety disorder, 77
 - obsessive-compulsive disorder, 77–78
 - overview, 60
 - panic disorder/agoraphobia, 78
 - phobias, 78, 80
 - posttraumatic stress disorder, 79
 - social anxiety disorder, 79–80
 - treatments chart, 76
- "Anxiety-related pathways"
 - anxiety neurobiology and, 36
- Anxiolytic drugs
 - anxiety disorder pharmacotherapy, 62–75
 - amino acid neurotransmission, 72–75
 - anticonvulsants, 74–75
 - antidepressants, 64–70
 - antihistamines, 75
 - antipsychotics, 71–72
 - benzodiazepines, 73–74
 - beta-blockers, 71
 - lithium, 75
 - monoamine neurotransmission, 63–72
 - serotonin and noradrenaline reuptake inhibitors, 69
 - serotonin receptor agonists, 70–71
 - tricyclic antidepressants, 69–70
- corticotropin-releasing factor receptor antagonists
 - future research issues, 198–199
 - nonpeptide ligands, 195–196
 - overview, 177–179
 - peptide ligand pharmacology, 185–195
 - ligand binding mechanisms, 190–195
 - receptor/ligand family structure, 179–185
 - ligand properties, 180–181
 - receptor subtypes and distribution, 181–185
 - therapeutic potential, 196–198
- Appetite regulation
 - cannabinoid receptors and, 670–672
- Arachidonic acid derivatives
 - endocannabinoid ligands, 663–664
 - transient receptor potential V1 (TRPV1) receptor expression, 732–733
- N*-Arachidonoyldopamine
 - endocannabinoid ligands, 663–664
- Arachidonylethanolamide
 - cannabinoid receptors and, 661–662
- O*-Arachidonylethanolamine
 - endocannabinoid ligands, 663–664
- Arousal
 - autonomic arousal
 - anxiety neurobiology, 4
 - animal anxiety-like behavior, 10–12
- Asenapine
 - schizophrenia therapy, 389
- Assembly mechanisms
 - GABA_A receptors
 - benzodiazepines, 108–110
- Astressin
 - corticotropin-releasing factor receptor antagonists
 - ligand binding mechanisms, 191–195

- Attention-deficit hyperactivity disorder (ADHD)
 obsessive-compulsive disorder
 comorbidity, 216
 psychostimulant therapy, 568–569, 587
 chronic exposure and sensitization effects, 581–585
- Attention deficits
 schizophrenia
 animal models, 263–264
- Augmentation strategies
 obsessive-compulsive disorders
 neuropharmacology, 225, 229–234
- Autonomic arousal
 anxiety neurobiology, 4
 animal anxiety-like behavior, 10–12
- Autoreceptors
 partial dopamine agonists, 416–417
- Avoidance behaviors
 anxiety neurobiology, 4
 animal anxiety-like behavior, 10–12
- Avolition
 in schizophrenia, 255–256
- Baclofen
 psychostimulant abuse therapy, 588
- Basal ganglia-thalamic-frontal loops
 obsessive-compulsive disorders
 neuropharmacology, 221–222
- BC1 RNA
 anxiety neurobiology and, 32
- Bed nucleus of stria terminalis (BST)
 alcohol abuse studies
 dopaminergic receptor systems and substrates, 473–475
- Behavioral inhibition/activity
 alcohol abuse
 animal models
 neuroanatomical substrates, 466–467
 behavioral paradigms, 467–470
 central nervous system circuitry, 470–471
 novel substrates, 471
 dopamine neuronal systems and substrates, 471–486
 bed nucleus of stria terminalis, 473–475
 dopaminergic regulation, early research, 472–473
 extracellular dopamine, 485–486
 future research issues, 517–518
 GABAergic interactions with, 486
 lateral hypothalamus, 481–485
 ventral pallidum, 476–480
- GABA_A benzodiazepine receptor complex, molecular biology, 487–501
 alcohol/modulator commonalities, 487–488
 CA1/CA3 hippocampus, 511–516
 efficacy of β CCT/3PBD modulation, GABA_{A1,2,3,5} receptors, 499–501
 future research issues, 517–518
 GABA-DA interaction hypothesis, 496–498
 ligand selectivity with GABA_{A1} subunits, 498–499
 microinjection studies, 505–506
 naltrexone antagonist, 507–511
 novel CNS GABAergic substrates, 498
 probe applications, 488–493
 site-specific microinjection, 493–496
 subunit selectivity vs. intrinsic efficacy, 516–517
 systemic administration, 492–493, 503–504
 ventral pallidum, 501–502
 overview, 466
 anxiety neurobiology, 4
 animal anxiety-like behavior, 10–12
 3,4-methylenedioxymethamphetamine effects, 616–619
 neurotoxic lesions and, 629–631
 neurosteroids, 142
 psychostimulant abuse
 chronic exposure and sensitization effects, 580–585
- Benzamides
 D₁, D₃, and D₄ receptors, 415–416
- Benzodiazepines (BZs). *See also* GABA_A benzodiazepine receptor complex
 anxiety disorder therapy, 73–74
 flunitrazepam, 637
 future research, 116–117
 GABA_A benzodiazepine receptor complex
 alcohol abuse studies, 487–501
 alcohol/modulator commonalities, 487–488
 CA1/CA3 hippocampus, 511–516
 efficacy of β CCT/3PBD modulation, GABA_{A1,2,3,5} receptors, 499–501
 future research issues, 517–518

- GABA-DA interaction hypothesis, 496–498
- ligand selectivity with GABA_{A1} subunits, 498–499
- microinjection studies, 505–506
- naltrexone antagonist, 507–511
- novel CNS GABAergic substrates, 498
- oral administration, β CCT/3PBD
 - anxiety reduction, 510–511
 - vs. naltrexone, 507–511
- probe applications, 488–493
- site-specific microinjection, 493–496
- subunit selectivity vs. intrinsic efficacy, 516–517
- systemic administration, 492–493, 503–504
- ventral pallidum, 501–502
- GABA_A receptors
 - assembly, clustering, and surface expression, 108–110
 - binding pocket, 105–108
 - brain function diversity, 110–112
 - functional diversity, knockout/knockin models, 112–114
 - single-cell response modulation, 99–100
 - structure and function, 93–96
 - subunit/subtype diversity, 103–104
- 3,4-methylenedioxymethamphetamine effects on, 628
- receptor ligand pharmacology, 97–102
 - endogenous site, 98–99
 - metabolism functions, 101–102
 - single-cell GABA response modulation, 99–100
- therapeutic action, 97–98
- tolerance and dependence characteristics, 100–101
- structure-activity relationships, 114–116
- structure and function, 93–96
- Beta-blockers
 - anxiety disorder therapy, 71
 - migraine management, 767
- BIBN4096BS compound
 - calcitonin gene-related peptide sites and migraine therapy targeting, 762–764
- Bicuculline
 - alcohol abuse studies
 - GABA_A benzodiazepine receptor complex, 487–488
 - site-specific microinjection techniques, 494–496
- Bifeprunox
 - schizophrenia therapy, 389
- Binding pocket structures
 - benzodiazepines
 - GABA_A receptors, 105–108
- Biochemical markers
 - in schizophrenia, 260–262
- Biochemistry
 - 3,4-methylenedioxymethamphetamine effects, 616–619
- Biogenesis of lysosome-related organelles complex-1 (BLOC1)
 - dystrobrevin binding protein 1 (DTNBP1) molecular interactions, 353
- Biological mechanisms
 - of schizophrenia, 256–263
- Blood alcohol concentration (BAC) levels
 - alcohol abuse studies in alcohol-preferring rats, 468–470
- Body temperature
 - 3,4-methylenedioxymethamphetamine effects on, 617–618
 - neurotoxicity and, 624–625
- Botulinium toxin (Botox)
 - migraine management, 768
- Brain
 - anxiety disorder-related regions of, 13–15
 - benzodiazepine distribution, 110–112
 - 3,4-methylenedioxymethamphetamine neurotoxicity
 - biochemical and functional changes, 631–632
 - neuroactive steroid sources, 135–137
 - neuroanatomical control regions
 - alcohol abuse studies in alcohol-preferring rats, 469–470
 - circuitry systems, 470–471
 - psychostimulant abuse, 574–575
- Brain-derived neurotrophic factor (BDNF)
 - anxiety neurobiology, 4
 - genetic susceptibility studies, 18–19
 - knockout mice studies, 25–26
 - receptor deficits and, 29–30
 - schizophrenia therapy
 - serotonin receptor 5-HT_{2A} receptor and, 421–422
- Brain imaging studies
 - obsessive-compulsive disorders, 217–222
 - animal models, 224

- neuropharmacological implications, 220–222
- schizophrenia, 256–260
- Buprenorphine
 - opiate addiction therapy
 - comparative efficacy studies, 697–698
 - implementation issues and pilot studies, 698
 - regulatory approval studies, 696–697
- Bupropion
 - nicotine dependence and withdrawal therapy, 549–550
- Buspirone
 - anxiety disorder therapy, 70–71
 - opiate addiction therapy, 699
- Butyrophenones
 - schizophrenia therapy
 - clinical profile, 383
- CA1/CA3 hippocampal fields
 - alcohol abuse studies
 - GABA_{A5} receptor probes, 511–516
- Calcitonin gene-related peptide (CGRP)
 - migraine therapy, 759–763
 - injection techniques, 763
 - neurovascular model, 759–760
 - receptor antagonist therapeutic efficacy, 763–764
 - synthesis and actions, 760–761
 - targeted repression therapy, 768
 - trigeminovascularity sites, 761–763
 - pain management applications, 768–769
- Calcitonin receptor-like receptor (CLR)
 - calcitonin gene-related peptide sites and migraine therapy targeting, 762
- Calcium/calmodulin-dependent protein kinase II (CaMK II)
 - anxiety neurobiology and, 30–33
 - benzodiazepine tolerance, 101
- Calcium channel blockers
 - migraine management, 767–768
 - vanilloid receptors and, 728–729
- Calmodulin kinase II
 - transient receptor potential V1 (TRPV1) receptor sensitization, 735
- cAMP response element binding (CREB) protein
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 585
- Cannabinoid hypothesis of schizophrenia
 - pharmacotherapy, 394
- Cannabinoid receptors. *See also* Marijuana
 - analgesic properties, 666–668
 - cannabinoid₁ (CB-1) receptor
 - addictive disorders
 - modulator therapy and, 458–459
 - antagonist/agonist medication
 - development, 700
 - anxiety neurobiology and
 - deficits in, 29–30
 - appetite regulation, 670–672
 - cognition and, 669–670
 - convulsant effects, 672–673
 - emesis modulation, 673–675
 - identification of, 661–662
 - nicotine dependence and withdrawal therapy
 - antagonist agents, 550
 - pain management and, 667–668
 - prenatal development and, 664–665
 - signaling mechanisms, 662–663
 - cannabinoid₂ (CB-2) receptor
 - emesis modulation, 674–675
 - pain management and, 668–669
 - signaling mechanisms, 662–663
 - cognition and, 669–670
 - convulsant effects, 672–673
 - emesis modulation, 673–675
 - future research on, 676
 - reward, tolerance, and dependence, 675–676
 - in schizophrenia
 - animal model, 265
 - signaling mechanisms, 662–663
- CAPON gene
 - schizophrenia molecular genetics, 328
- Capsaicin
 - cloning of, 727–729
 - transient receptor potential V1 (TRPV1) receptor expression, 730–732
- Carbamazepine
 - anxiety disorder therapy, 75
- β -Carboline-3-carboxylate-*t*-butyl ester
 - alcohol abuse studies
 - anxiety reduction with, 510–511
 - GABA_{A1,2,3,5} receptor subunit modulation, 499–501
 - GABA_{A1} receptor subunit selectivity, 498–499
 - microinjection techniques, 505–507
 - oral administration, 507–511
 - systemic administration, 503–504

- β -Carboline antagonist ZK 93426
 - alcohol abuse studies
 - GABA_{A5} receptor specificity, 514–516
 - GABA_A benzodiazepine receptor complex, 490–493
 - GABAergic modification of dopamine agonists, 497
- Cardiovascular system
 - γ -hydroxybutyric acid (GHB) effects, 634
- Caspase-1
 - 3,4-methylenedioxyamphetamine effects on, 628
- Catechol-*O*-methyl transferase (COMT)
 - anxiety neurobiology and knockout mice studies, 24–26
 - obsessive-compulsive disorders metabolism studies, 223
 - schizophrenia
 - dopamine hypothesis, 373
 - genetic evidence, 286–287
 - genetics studies, 286–287
 - imaging studies, 285–286
 - molecular genetics
 - chromosomal abnormalities, 328–329
 - susceptibility gene identification, 347–348
 - tolcapone targeting of, 389
- Cell-cell interactions
 - anxiety neurobiology neuronal deficits and, 30
- Cell membrane-associated proteins
 - anxiety neurobiology and mouse studies, 19, 21
- Central nervous system (CNS)
 - alcohol abuse studies in alcohol-preferring rats
 - circuitry systems, role of, 470–471
 - control substrates, 469–470
 - γ -hydroxybutyric acid (GHB) effects, 634
 - pain pathways, 712–714
 - schizophrenia and, 260–262
- Cerebrospinal fluid (CSF)
 - corticotropin-releasing factor receptor antagonists
 - effects on, 177–179
 - schizophrenia dopamine hypothesis and, 288–289
- C fibers
 - pain pathways, 711–712
 - transient receptor potential V1 (TRPV1) receptor expression, 729
- Chemotherapy
 - emesis with
 - cannabinoid modulation of, 674–675
- Cholecystokinin
 - anxiety neurobiology and, 17
 - pain management and, 716–717
- Cholinergic neurotransmitters
 - atypical antipsychotic mechanisms, 429–430
 - schizophrenia neurochemistry and, 261–262
 - schizophrenia pharmacotherapy, 393–394
- Chromosomal abnormalities
 - schizophrenia molecular genetics, 328–331
 - catechol-*O*-methyltransferase, 328–329
 - DISC1 gene, 330–331
 - PRODH candidate gene, 329–330
 - ZDHHC8 candidate gene, 330
- Chromosome mapping
 - anxiety neurobiology mouse studies, 19, 23
 - schizophrenia
 - susceptibility gene identification, 346–351
- CL218,872
 - alcohol abuse studies
 - GABA_{A1} receptor subunit selectivity, 499
- Clomipramine
 - obsessive-compulsive disorder therapy, 69–70
- Clonazepam
 - obsessive-compulsive disorder therapy, 234
- Clonidine
 - schizophrenia pharmacotherapy, 393
- Clozapine
 - dopamine D₂ receptor blockade, 412–415
 - mechanisms of action
 - cholinergic mechanisms, 429–430
 - serotonin receptor 5-HT_{2A}, 418–421, 420–421
 - serotonin receptor 5-HT₆ and, 425–426
 - serotonin receptor 5-HT/D₂ hypothesis, 417–418
 - schizophrenia therapy
 - brain-derived neurotrophic factor and, 421–422
 - cholinergic receptor targeting, 393–394
 - clinical profile, 387
 - dopamine D₂ receptor blockade, 412–415

- history of, 370
 - safety and tolerability, 388–389
 - schizophrenia-related psychosis, 254
- Clusters
 - GABA_A receptors
 - benzodiazepines, 108–110
- Cocaine
 - abuse
 - 3,4-methylenedioxymethamphetamine
 - reinforcement of, 615–616
 - monoamine neuropharmacology, 570–575
 - therapy developments for, 585–588
 - chronic exposure and sensitization effects, 580–585
 - neuropeptide pharmacology and, 578–579
- Cocaine- and amphetamine-regulated transcript (CART) peptides
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 585
- Cognitive behavior therapy (CBT)
 - obsessive-compulsive disorders, 219–220
- Cognitive function
 - cannabinoid receptors and, 669–670
 - 3,4-methylenedioxymethamphetamine
 - and, 630–631
 - nicotine dependence and withdrawal
 - withdrawal neurosubstrates, 541–543
 - schizophrenia, 254–255
 - animal model, 263–264
 - glutamatergic receptors, 428–429
 - neural network analysis, 259
 - serotonin receptor 5-HT_{2A} receptor
 - enhancement, 421–422
- Comorbid conditions
 - addictive disorders vulnerability with, 457–458
 - obsessive-compulsive disorders, 216
 - opiate addiction, 691–694
- Compensatory mechanisms
 - dopamine hypothesis of schizophrenia, 284–285
- Computed tomography (CT)
 - obsessive-compulsive disorders
 - brain imaging studies, 217–218
 - schizophrenia analysis, 256
- Conditioned conflict tests
 - anxiety neurobiology
 - emotionality studies in mice, 8–9
- Conditioned fear paradigms
 - emotionality studies in mice, 8–9
- Continuous performance test (CPT)
 - schizophrenia
 - animal models, 263–264
- Cortical dopamine
 - schizophrenia dopamine hypothesis and, 287–288
 - serotonin receptor 5-HT_{2A} receptor
 - enhancement, 421–422
- Corticosterone
 - psychostimulant abuse, 577–578
- Corticostriatal-thalamic-cortical loops
 - integrated glutamate/dopamine
 - hypotheses of schizophrenia
 - neurochemistry and, 374–376
- Corticotropin-releasing factor (CRF)
 - alcohol abuse studies
 - in alcohol-preferring rats, 471
 - neurosteroid effects
 - acoustic/fear-potentiated startle, 147
 - nicotine dependence and withdrawal, 539–540
 - withdrawal substrate specificity, 543
 - opiate dependence therapy and, 699
 - psychostimulant abuse, 577–578
 - chronic exposure and sensitization effects, 580–585
- Corticotropin-releasing factor receptor
 - antagonists
 - anxiolytic applications
 - future research issues, 198–199
 - nonpeptide ligands, 195–196
 - overview, 177–179
 - peptide ligand pharmacology, 185–195
 - ligand binding mechanisms, 190–195
 - receptor/ligand family structure, 179–185
 - ligand properties, 180–181
 - receptor subtypes and distribution, 181–185
 - therapeutic potential, 196–198
- Corticotropin-releasing hormone (CRH)
 - anxiety neurobiology and, 17
 - knockout mice studies, 25–26
 - receptor deficits, 28–30
- Cortisol
 - nicotine dependence and withdrawal, 539–540
 - withdrawal substrate specificity, 543
- Cotinine
 - nicotine dependence and withdrawal
 - metabolism and elimination
 - pharmacokinetics, 544–545

- Countermodulation therapy
 - addictive disorders, 458–459
- CP-154,526 antagonist
 - opiate dependence therapy and, 699
- CRF₁ receptor
 - corticotropin-releasing factor receptor antagonists, 181–185
 - anxiety/depression therapeutic potential and, 196–198
 - ligand binding mechanisms, 190–195
 - nonpeptide ligands, 195–196
 - peptide ligand pharmacology, 185–195
- CRF_{2(a)} receptor
 - corticotropin-releasing factor receptor antagonists, 182–185
- CRF_{2(b)} receptor
 - corticotropin-releasing factor receptor antagonists, 182–185
- CRF₂ receptor
 - corticotropin-releasing factor receptor antagonists, 182–185
 - ligand binding mechanisms, 190–195
 - peptide ligand pharmacology, 185–195
- CX516 compound
 - schizophrenia pharmacotherapy, 392
- Cyclic adenosine monophosphate (cAMP)
 - corticotropin-releasing factor receptor antagonists
 - CRF receptor stimulation, 186–195
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 584–585
- Cyclic adenosine monophosphate (cAMP)-responsive nuclear factors
 - anxiety neurobiology and, 32
- CYP1A2 enzyme
 - 3,4-methylenedioxymethamphetamine neurotoxicity and, 622
- CYP2A6 enzyme
 - nicotine dependence and withdrawal
 - metabolism and elimination
 - pharmacokinetics, 545
- Cystine/glutamate transporters
 - psychostimulant abuse and, 576
- Cytochrome P450 enzymes
 - benzodiazepine receptor ligand
 - metabolism, 102
 - selective serotonin reuptake inhibitors, 68–69
- Cytogenetic abnormalities
 - schizophrenia
 - susceptibility gene identification, 346–351
- Cytokines
 - anxiety neurobiology, 16–18
 - knockout mice studies, 26
 - 3,4-methylenedioxymethamphetamine
 - effects on, 627–628
- D₁ receptor
 - alcohol abuse studies
 - bed nucleus of stria terminalis system, 475
 - lateral hypothalamus, dopaminergic regulation by, 481–485
 - ventral pallidum pathways, 477–480
 - psychostimulant abuse
 - monoamine neuropharmacology, 571–575
 - schizophrenia dopamine hypothesis
 - cortical vs. striatal dopamine, 288
 - history, 284–285
 - imaging evidence, 286–287
 - schizophrenia pharmacotherapy
 - antipsychotic agents, 380–381
 - schizophrenia therapy
 - agonist and antagonists, 390
 - substituted benzamides, 415–416
- D₂/D₃ receptors
 - clozapine D₂ receptor blockade, 414–415
 - partial dopamine agonists, 416–417
 - psychostimulant abuse therapy, 586–587
 - selective antagonism
 - schizophrenia therapy, 380
 - substituted benzamides, 416
- D₂ receptor
 - alcohol abuse studies
 - lateral hypothalamus, dopaminergic regulation by, 481–485
 - ventral pallidum pathways, 477–480
 - clozapine blockade, 412–415
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 582–585
 - monoamine neuropharmacology, 571–575
 - schizophrenia dopamine hypothesis
 - cortical vs. striatal dopamine, 288
 - history, 284–285, 371–373
 - imaging evidence, 285–286
 - pathological evidence, 285
 - pharmacological evidence, 287

- schizophrenia pharmacotherapy
 - antipsychotic occupancy and effect, 376–378
 - High 5-HT_{2A} vs., 378
 - occupancy thresholds and rapid dissociation, 378–380
 - subtherapeutic occupancy time, 382
- D₃ receptor
 - schizophrenia dopamine hypothesis
 - genetic evidence, 286–287
 - pathological evidence, 285
 - pharmacological evidence, 287
 - schizophrenia therapy
 - antagonist development, 390
 - substituted benzamides, 415–416
- D₄ receptor
 - schizophrenia dopamine hypothesis
 - pathological evidence, 285
 - pharmacological evidence, 287
 - schizophrenia therapy
 - antagonism and regional specificity, 380
 - antagonist development, 390
 - substituted benzamides, 415–416
- Deep brain stimulation (DBS)
 - obsessive-compulsive disorders, 236–237
- Defensive burying behavior
 - animal anxiety models
 - neurosteroid effects, 149–150
- Dehydroepiandrosterone
 - schizophrenia therapy, 394
- Dehydroepiandrosterone sulfate (DHEAS)
 - in brain, 137
 - schizophrenia therapy, 394
- Delta opioid receptors
 - structure and function, 751
- Dependency risk
 - endocannabinoids, 675–676
- Depolarization inactivation
 - schizophrenia therapy
 - D₂ receptor occupancy and effect, 376–378
- Depression
 - anxiety symptoms with
 - pharmacotherapy, 80
 - corticotropin-releasing factor receptor
 - antagonists
 - therapeutic potential of, 196–198
 - neuroactive steroid interactions, 156–157
 - stress-induced behavior
 - neuroactive steroids, 156–157
- Desensitization
 - transient receptor potential V1 (TRPV1) receptors, 735–736
- Designer drugs. *See also* specific drugs, e.g. 3,4-Methylenedioxy-methamphetamine (MDMA)
 - overview, 614
- Developmental genes
 - obsessive-compulsive disorders, 223–224
- Diagnostic criteria
 - anxiety disorders, 9–12, 61–62
- Diazepam binding inhibitor (DBI)
 - benzodiazepine ligands, 98–99
- 3,4-Dihydroxyamphetamine (HHA)
 - 3,4-methylenedioxymethamphetamine
 - neurotoxicity and, 622
- 3,4-Dihydroxy-L-phenylalanine (DOPA)
 - schizophrenia dopamine hypothesis, 372–373
- Dimerization
 - opioid receptors, 752
- DISC1 gene
 - schizophrenia molecular genetics, 330–331
 - molecular interactions, 351–352
 - susceptibility identification, 349–350
- Discontinuation syndrome
 - selective serotonin reuptake inhibitors, 67–69
- Distribution kinetics
 - nicotine dependence and withdrawal, 544
- DOI
 - hallucinogens and, 639
 - schizophrenia therapy
 - serotonin receptor 5-HT_{2A}, 420–421
- Donepezil
 - schizophrenia pharmacotherapy, 393–394
- Dopadecarboxylase
 - schizophrenia dopamine hypothesis, 372–373
- Dopamine agonist
 - alcohol abuse studies
 - GABAergic modification, 496–498
 - partial agonists, 416–417
 - psychostimulant abuse therapy, 586–587
 - in schizophrenia
 - animal models, 264
- Dopamine hypothesis of schizophrenia
 - cortical vs. striatal dopamine, 287–289
 - genetic evidence, 286–287
 - glutamate theory consolidated with, 295–296
 - history, 284–285

- imaging evidence, 285–286
- neurochemistry and, 371–373
- pathological evidence, 285
- pharmacological evidence, 287
- postmortem studies, 344
- Dopamine neurotransmitters
 - addictive disorders
 - reward therapy and, 458–459
 - anxiety disorder therapy
 - antipsychotics, 71–72
 - anxiety neurobiology, 15–17
 - receptor deficits, 29–30
 - 3,4-methylenedioxymethamphetamine (MDMA)
 - receptor/transporter effects, 617
 - reinforcing properties, 614–616
 - nicotine dependence and withdrawal
 - withdrawal substrates, 542–543
 - obsessive-compulsive disorders, 223
 - psychostimulant abuse, 569–575
 - neuropeptide pharmacology, 579
 - neuropharmacology, 570–575
 - schizophrenia and, 260–262
 - COMT catabolism and, 328
 - drug targeting innovations, 389
- Dopaminergic receptors
 - alcohol abuse studies
 - neuronal systems and substrates, 471–486
 - bed nucleus of stria terminalis, 473–475
 - dopaminergic regulation, early
 - research, 472–473
 - extracellular dopamine, 485–486
 - future research issues, 517–518
 - GABAergic interactions with, 486
 - lateral hypothalamus, 481–485
 - D₂ dopaminergic regulation, hypothesized mechanisms, 481–485
 - ventral pallidum, 476–480
 - hypothesized mechanisms, 478–480
 - alcohol abuse studies
 - in alcohol-preferring rats, 471
 - anxiety neurobiology and receptor deficits, 29–30
 - nicotine dependence and withdrawal
 - nicotine reinforcement substrates, 538–540
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 582–585
 - glutamatergic interactions, 575–576
 - monoamine neuropharmacology, 571–575
 - schizophrenia molecular genetics
 - functional candidate genes, 331–332
- Dopamine transporter
 - catechol-*O*-methyl transferase
 - as schizophrenia susceptibility gene, 347–348
 - inhibitors
 - psychostimulant therapy targeting, 587–588
 - obsessive-compulsive disorders
 - abnormalities, 219–220
 - psychostimulant abuse
 - monoamine neuropharmacology, 573–575
 - schizophrenia
 - dopamine hypothesis and, 285
- Dorsolateral prefrontal cortex (DLPFC)
 - schizophrenia dopamine hypothesis, 373
- DRD2/DRD3 receptors
 - schizophrenia molecular genetics, 331–332
 - catechol-*O*-methyl transferase
 - susceptibility gene, 347–348
- Drug abuse
 - dopaminergic receptor systems and substrates
 - bed nucleus of stria terminalis system, 474–475
 - rewarding/reinforcing effects in, 459
 - stress-induced response
 - neuroactive steroid effects and, 159–160
- Dyadic encounters
 - schizophrenia
 - animal models, 264
- Dynorphins
 - structure and classification, 747
- Dysbindin
 - dystrobrevin binding protein 1 (DTNBP1)
 - molecular interactions, 353
 - schizophrenia candidate gene, 326, 348–349
- Dystrobrevin binding protein 1 (DTNBP1)
 - schizophrenia candidate gene, 325–326
 - chromosome mapping, 346
 - chromosome identification of, 348–349
 - functional implications, 332–333
 - molecular interactions, 352–353
- Dystrophini-associated glycoprotein complex (DCG)

- dystrobrevin binding protein 1
 - identification
 - schizophrenia candidate gene, 348–349
- Electroencephalography (EEG)
 - schizophrenia analysis, 256
- Elevated-plus maze (EPM)
 - animal anxiety-like behavior and, 12
 - neurosteroid effects, 143–145
 - emotionality studies in mice, 7–9
- Elevated-zero maze (EZM)
 - emotionality studies in mice, 8–9
- Elimination mechanisms
 - nicotine dependence and withdrawal, 544–545
- Emesis
 - antiemetics
 - migraine management, 765
 - cannabinoid receptors modulation of, 673–675
- Emotionality studies
 - anxiety neurobiology
 - rodent models, 6–9
- Enantiomeric selectivity
 - neuroactive steroids, 141–142
- Endocannabinoid system, 662–665
 - cannabinoid receptors and signaling, 662–663
 - physiology and pharmacology, 665–675
 - prenatal developmental effects, 664–665
 - reward, tolerance and dependence mechanisms, 675–676
 - synthesis and metabolism, 663–664
- Endogenous opioids
 - classification, 746–748
- Endogenous sites
 - benzodiazepine ligands, 98–99
- β -Endorphins
 - structure and classification, 747–748
- Enkephalin neurons
 - nicotine dependence and withdrawal, 540
- Enkephalins
 - structure and function, 746–747
- Enthoprotin
 - schizophrenia molecular genetics, 328
- Environmental factors
 - addictive disorders vulnerability, 457–458
 - anxiety neurobiology
 - early-life experience, 33–34
- Epilepsy
 - endocannabinoids and, 672–673
- ErbB3 gene
 - NRG1 molecular interaction, 353–355
 - regulator of G-protein signaling 4
 - schizophrenia candidate gene, 328
- Ergots
 - migraine management, 765
- Ethanol
 - neuroactive steroid effects and, 158–159
- Eticlopride
 - alcohol abuse studies
 - lateral hypothalamus, effects on, 481–485
 - ventral pallidum receptor blockade, 478
- Excitatory amino acid transporters (EAATs)
 - glutamate theory of schizophrenia
 - pathological evidence, 292
 - schizophrenia genetics
 - GRM3 gene, 349
- Extended amygala (EA)
 - alcohol abuse studies
 - dopaminergic receptor systems and substrates, 473–474
 - GABA_A benzodiazepine receptor complex manipulation
 - site-specific microinjection studies, 493–496
- Extracellular dopamine
 - alcohol abuse studies
 - dopaminergic regulation mechanisms, 485–486
- Extrapyramidal symptoms (EPS)
 - atypical antipsychotic drugs, 411–412
 - clozapine D₂ receptor blockade, 412–415
 - schizophrenia therapy
 - antipsychotics and, 370–371
 - D₂ receptor occupancy and effect, 376–378
 - D₂ receptor occupancy thresholds and rapid dissociation, 379–380
 - first-generation antipsychotics, 383
 - second-generation antipsychotics, 383–388
 - serotonin receptor 5-HT_{2A} blockade, 422
- Extroversion *vs.* introversion (E trait)
 - anxiety neurobiology, 5–6
- Face validity
 - animal anxiety-like behavior and, 12
- Fatty acid amide hydrolase (FAAH)
 - convulsant effects of, 672–673
 - emesis modulation, 674–675

- endocannabinoid ligands, 664
- endocannabinoid physiology and, 666
- Fear/anxiety circuits
 - anxiety neurobiology, 13–15
- Fear-potentiated startle
 - mouse anxiety models
 - neurosteroid effects, 147
- Feverfew
 - migraine management, 768
- FEZ1 protein
 - DISC1 schizophrenia candidate gene
 - molecular interactions, 351–352
- First-generation antipsychotics (FGAs)
 - schizophrenia therapy
 - clinical profiles, 383
 - D₂ receptor occupancy and effect, 376–378
 - history of, 370–371
 - NMDA receptor antagonists, 381
 - second-generation antipsychotic comparisons, 384–387
- Fixed-ratio (FR) schedule
 - alcohol abuse studies in alcohol-preferring rats, 469
- Flumazenil
 - alcohol abuse studies
 - GABA_{A5} receptor specificity, 512–516
 - GABA_A benzodiazepine receptor complex, 490–493
 - endogenous ligand sites, 98–99
- Flunitrazepam
 - overview, 637
- Fluorodeoxyglucose (FDG) studies
 - schizophrenia analysis, 257
- Fluoxetine
 - 3,4-methylenedioxymethamphetamine effects on, 616, 627
 - nicotine dependence and withdrawal
 - withdrawal substrate specificity, 542–543
- Fluphenazine
 - adrenergic receptor mechanisms, 427
- Free-radical formation
 - 3,4-methylenedioxymethamphetamine neurotoxicity, 624
- Frontal cortex abnormalities
 - glutamate theory of schizophrenia
 - pathological evidence, 292
- Functional candidate genes
 - schizophrenia molecular genetics, 331–332
- Functional imaging studies
 - obsessive-compulsive disorders, 219–220
 - schizophrenia analysis, 257–260
- Fyn tyrosine kinase
 - anxiety neurobiology and, 31
- GABA_A-benzodiazepine receptor complex
 - alcohol abuse studies, 487–501
 - alcohol/modulator commonalities, 487–488
 - CA1/CA3 hippocampus, 511–516
 - efficacy of β CCT/3PBD modulation, GABA_{A1,2,3,5} receptors, 499–501
 - future research issues, 517–518
 - GABA-DA interaction hypothesis, 496–498
 - ligand selectivity with GABA_{A1} subunits, 498–499
 - microinjection studies, 505–506
 - naltrexone antagonist, 507–511
 - novel CNS GABAergic substrates, 498
 - oral administration, β CCT/3PBD
 - anxiety reduction, 510–511
 - vs. naltrexone, 507–511
 - probe applications, 488–493
 - site-specific microinjection, 493–496
 - subunit selectivity vs. intrinsic efficacy, 516–517
 - systemic administration, 492–493, 503–504
 - ventral pallidum, 501–502
- GABAergic neurons
 - alcohol abuse studies
 - in alcohol-preferring rats, 471
 - bed nucleus of stria terminalis system, 474
 - dopamine agonist modification, 496–498
 - GABA_{A5} receptor specificity, 512–516
 - novel substrates, 498
 - ventral pallidum dopaminergic regulation and, 479–480
- cannabinoid₁ (CB-1) receptors and, 672–673
- integrated glutamate/dopamine hypotheses of schizophrenia, 375–376
- psychostimulant abuse, 574–575
 - chronic exposure and sensitization effects, 583–585
- γ -aminobutyric acid (GABA) receptors and, 576–577
- novel therapeutic developments, 588

- Gabapentin
 anxiety disorder therapy
 amino acid neurotransmission, 75
 migraine management, 766–767
- GA-BARAP
 GABA_A receptors
 benzodiazepines, 109–110
- "GABA shift" assay
 alcohol abuse studies
 GABA_A benzodiazepine receptor complex
 subunit selectivity vs. intrinsic efficacy, 517
- Galantamine
 schizophrenia pharmacotherapy, 393–394
- γ -aminobutyric acid (GABA) receptors
 addictive disorders
 modulator therapy and, 458–459
 anxiety disorder therapy
 amino acid neurotransmission, 72–75
 anxiety neurobiology and, 15–17
 knockout mice deficit studies, 26–30
 cannabinoid receptors and neurotoxicity effects, 673
- GABA_A receptors
 alcohol abuse studies
 novel substrates, 498
 ventral pallidum dopaminergic regulation and, 479–480
 benzodiazepines
 assembly, clustering, and surface expression, 108–110
 binding pocket, 105–108
 brain function diversity, 110–112
 functional diversity, knockout/knockin models, 112–114
 single-cell response modulation, 99–100
 subunit/subtype diversity, 103–104
- GABA_{A1} subunit
 alcohol abuse studies, 498–501
 microinjection techniques, 505–507
 ventral pallidum selectivity, 501–503
- GABA_{A5} subunit
 as alcohol substrate probes, 511–516
 neuroactive steroids, 137–141
- GABA_B receptors
 alcohol abuse studies
 ventral pallidum dopaminergic regulation and, 479–480
- γ -hydroxybutyric acid (GHB)
 mechanisms and, 634–635
 migraine management with anticonvulsants, 766–767
 neuroactive steroids
 enantiomeric selectivity, 141–142
 nicotine dependence and withdrawal
 nicotine reinforcement substrates, 538–540
 NRG1 molecular interaction, 354–355
 psychostimulant abuse and, 576–577
 schizophrenia neurochemistry and, 261–262
- γ -hydroxybutyric acid (GHB)
 addiction risk, 635–636
 mechanism of action, 634–635
 overview, 632–633
 pharmacological effects, 633–634
- "Gate control" theory
 classification of, 713–714
- Geller-Seifter test
 mouse models of anxiety, 8–9
 neurosteroid effects, 145–146
- Gene expression
 psychostimulant abuse
 chronic exposure and sensitization effects, 584–585
- Gene linkage studies
 schizophrenia, 323–324
 future research issues, 355–356
 susceptibility gene identification, 344–351
- Generalized anxiety disorder (GAD)
 buspirone therapy, 71
 pharmacotherapy, 77
 serotonin/noradrenaline reuptake inhibitors, 69
 tricyclic antidepressants, 69–70
- Genetic studies. *See also* Gene linkage studies; Molecular genetics
 addictive disorders vulnerability, 457–458
 anxiety neurobiology, 4–6
 environmental effects and, 34–35
 susceptibility studies, 18–19
 glutamate theory of schizophrenia, 293–294
 obsessive-compulsive disorders, 222–224
 developmental genes, 223–224
 dopamine, 223
 glutamate, 223
 neurotransmitter metabolism, 223
 serotonin, 222–224

- schizophrenia, 262–263
 - animal models, 264
 - dopamine hypothesis, 286–287
 - epidemiology, pathophysiology, and neurobiology, 323
- Gepirone
 - anxiety disorder therapy, 71
- Glia-derived protein
 - GABA_A receptors
 - benzodiazepines, 108–110
- Glucocorticoid receptor (GR)
 - stress-induced behaviors
 - neuroactive steroids, 153–154
- Glucocorticoid receptor (GR) transcription factor
 - anxiety neurobiology and, 31
- Glucocorticoids
 - anxiety neurobiology and, 17
- Glucocortical hormones
 - psychostimulant abuse, 577–578
- Glucose utilization
 - schizophrenia psychosis
 - neural network analysis, 257–258
- Glutamate neurotransmitters
 - anxiety disorder therapy
 - amino acid neurotransmission, 72–75
 - nicotine dependence and withdrawal
 - withdrawal substrates, 542–543
 - obsessive-compulsive disorders, 223
 - pain management and, 717
 - psychostimulant abuse and, 575–576
 - schizophrenia neurochemistry and, 261–262
 - targeted drug development for, 391–392
- Glutamate reuptake inhibitors
 - schizophrenia pharmacotherapy, 391–392
- Glutamatergic system
 - addictive disorders
 - modulator therapy and, 458–459
 - atypical antipsychotics, 427–428
 - nicotine dependence and withdrawal
 - nicotine reinforcement substrates, 538–540
 - psychostimulant abuse, 569–576
 - chronic exposure and sensitization effects, 583–585
 - novel therapeutic developments, 588
 - in schizophrenia, 264
 - molecular genetics
 - functional candidate genes, 331–332
 - pharmacotherapy
 - glutamate reuptake inhibitors, 391–392
- Glutamate theory of schizophrenia
 - dopamine hypothesis and, 295–296
 - genetic evidence for, 293–294
 - history, 289–291
 - imaging evidence for, 292–293
 - neurochemistry of, 373–374
 - pathological evidence for, 291–292
 - pharmacological evidence for, 294–295
- Glutamic acid decarboxylase (GAD)
 - anxiety neurobiology and
 - knockout mice studies, 24–26
 - schizophrenia susceptibility genetics, 350–351
- Glutathione conjugates
 - 3,4-methylenedioxymethamphetamine
 - neurotoxicity and, 622
- Glycine
 - schizophrenia pharmacotherapy
 - NMDA targeting with, 391–392
- Glycine transporter 1 (GlyT1)
 - glutamate theory of schizophrenia
 - pharmacological evidence, 294–295
- Glycine transporter inhibitors
 - schizophrenia pharmacotherapy
 - NMDA targeting with, 391–392
- G-protein coupled receptors (GPCRs)
 - corticotropin-releasing factor receptor
 - antagonists
 - ligand binding mechanisms, 192–195
 - delta opioid receptors, 751
 - kappa opioid receptors, 751–752
 - mu opioid receptors and, 748–751
 - regulator of G-protein signaling 4
 - schizophrenia candidate gene, 328
- G-protein-gated inwardly rectifying K⁺ (GIRK) channels
 - anxiety neurobiology and
 - receptor deficits and, 29–30
- G proteins
 - cannabinoid receptors and, 662–663
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 584–585
- GRM3 gene
 - schizophrenia molecular genetics, 331–332
 - susceptibility identification, 349
- Group A β -hemolytic streptococcus (GABHS) infection
 - obsessive-compulsive disorders and, 235

- Guanfacine
schizophrenia pharmacotherapy, 393
- Hallucinogens
LSD, 637–640
addiction, 639–640
mechanism of action, 638–639
pharmacology, 638
- Haloperidol
serotonin receptor 5-HT₆ and, 425–426
- Hamilton depression and anxiety scales
corticotropin-releasing factor receptor antagonists
anxiety/depression therapeutic potential, 197–198
- Heat exposure
transient receptor potential V1 (TRPV1)
receptor expression, 730–732
- Hepatitis C
opiate addiction comorbidity with, 691–694
- Heroin addiction
incidence and prevalence, 692–694
neuropeptide pharmacology and, 578–579
pharmacotherapy
history of, 451–457
treatment statistics, 694–696
- High 5-HT_{2A}
schizophrenia therapy
D₂ affinity *vs.*, 378
- High alcohol drinking (HAD) rats
alcohol abuse studies
characteristics of, 467
- Hippocampus
alcohol abuse studies
CA1/CA3 fields
GABA_{A5} receptor probes, 511–516
anxiety disorders and, 13–15
3,4-methylenedioxyamphetamine effects on
long-term neurochemical effects, 619–620
- Homeobox genes
obsessive-compulsive disorders, 223–224
- HTR2A receptor
schizophrenia molecular genetics, 331–332
- Human immunodeficiency virus
opiate addiction and exposure to, 691–694
- Hydroxyl radicals
3,4-methylenedioxyamphetamine neurotoxicity and, 627
- Hydroxyzine
anxiety disorder therapy, 75
- Hyperdopaminergic state
schizophrenia dopamine hypothesis and evidence for, 287
- Hyperthermia
3,4-methylenedioxyamphetamine neurotoxicity and, 624–625
- Hypodopaminergia
schizophrenia dopamine hypothesis, 288–289
- Hypothalamic-pituitary-adrenal (HPA) axis
anxiety neurobiology and, 17
corticotropin-releasing factor receptor antagonists, 177–179
nicotine dependence and withdrawal
nicotine reinforcement substrates, 539–540
withdrawal substrate specificity, 543
psychostimulant abuse, 577–578
chronic exposure and sensitization effects, 580–585
stress-induced behaviors
neuroactive steroids, 153–159
- Idazozan
adrenergic receptor mechanisms, 427
- Iloperidone
schizophrenia therapy, 389
- Imaging studies
brain regions
anxiety disorders and, 13–15
glutamate theory of schizophrenia, 292–293
schizophrenia
dopamine hypothesis, 285–286
- Imidazobenzodiazepines
alcohol abuse studies
GABA_{A5} receptor specificity, 512–516
- Immediate early genes
psychostimulant abuse
chronic exposure and sensitization effects, 585
- Immune response
3,4-methylenedioxyamphetamine effects on, 618
- Immunoglobulin therapy
obsessive-compulsive disorders, 235
- Immunomodulatory therapy
obsessive-compulsive disorders, 235
- Indole agents
serotonin receptor 5-HT_{2A}, 418–421

- Indolealkylamines, 637–640
 addiction, 639–640
 mechanism of action, 638–639
 pharmacology, 638
- Infection
 obsessive-compulsive disorders and, 235
- Inflammation
 transient receptor potential V1 (TRPV1) receptor expression, 729
- Integrated glutamate/dopamine hypotheses of schizophrenia
 basic principles, 295–297
 pharmacotherapy and, 374–376
- Interleukin-1 β converting enzyme (ICE)
 3,4-methylenedioxyamphetamine effects on, 628
- Interleukin-1 β release
 3,4-methylenedioxyamphetamine effects on, 628
- Intracellular signaling molecules
 anxiety neurobiology and mouse studies, 19, 22
 phenotype analysis, 30–33
 psychostimulant abuse
 chronic exposure and sensitization effects, 584–585
 schizophrenia therapy, 394–395
- Intrinsic efficacy
 alcohol abuse studies
 GABA_A benzodiazepine receptor complex
 subunit selectivity *vs.*, 516–517
- Ionotropic glutamate receptors
 atypical antipsychotics, 427–429
- J-domain fragments
 corticotropin-releasing factor receptor antagonists
 ligand binding mechanisms, 192–195
- Kainate receptors
 glutamate theory of schizophrenia mRNA binding, 291–292
 schizophrenia pharmacotherapy drug development for, 392
- Kappa opioid receptors
 psychostimulant abuse and, 578–579
 structure and function, 751–752
- Ketamine
 glutamate theory of schizophrenia history of, 289–290
 overview, 636
 pharmacological effects, 636–637
- Ketoconazole
 psychostimulant abuse, 577–578
- Knockin mice
 benzodiazepine functional diversity, 112–114
- Knockout mice
 anxiety neurobiology
 neuronal messenger alterations, 24–26
 neurotransmitter receptor/CMAP deficits, 26–30
 benzodiazepine functional diversity studies, 112–114
 calcitonin gene-related peptide studies, 760–761
 transient receptor potential V1 (TRPV1) receptor models, 736
- LAAM (λ - α -Acetyl methadol)
 addiction pharmacotherapy and, 454–457
 treatment statistics, 695–696
- Lamotrigine
 anxiety disorder therapy, 75
 schizophrenia pharmacotherapy
 NMDA targeted drug development, 392–393
- Lateral hypothalamus (LH)
 alcohol abuse studies
 dopamine neuronal systems and substrates, 481–485
 D₂ dopaminergic regulation, hypothesized mechanisms, 481–485
- Leptin
 cannabinoid receptors and, 671–672
- Lesion models
 in schizophrenia, 265
- Ligand-gated ion channels
 neuroactive steroids, 137–141
- Light-dark box
 mouse models of anxiety
 neurosteroid effects, 146–147
- LIS1 gene
 DISC1 schizophrenia candidate gene molecular interactions, 351–352
- Lithium
 anxiety disorder therapy, 75
- Locomotor sensitization
 psychostimulant abuse
 chronic exposure and sensitization effects, 581–585

- Lofexidine
 opiate addiction and, 699
- Long-term therapy
 selective serotonin reuptake inhibitors,
 68–69
- LY206130
 nicotine dependence and withdrawal
 withdrawal substrate specificity,
 542–543
- LY274600
 nicotine dependence and withdrawal
 withdrawal substrate specificity,
 542–543
- LY354740 Glu analog
 nicotine dependence and withdrawal
 withdrawal substrate specificity,
 542–543
- Lysergic acid diethylamide (LSD), 637–640
 addiction, 639–640
 mechanism of action, 638–639
 pharmacology, 638
- M100907 compound
 schizophrenia therapy
 serotonin receptor 5-HT_{2A}, 419–421
- Magnetic resonance imaging (MRI)
 obsessive-compulsive disorders
 brain imaging studies, 217–218, 220
 schizophrenia analysis, 256
- Magnetic resonance spectroscopy (MRS)
 glutamate theory of schizophrenia, 293
 schizophrenia analysis, 256–257
- MAPK/ERK signaling
 anxiety neurobiology and, 36–37
- Marijuana
 endocannabinoid system, 662–665
 cannabinoid receptors and signaling,
 662–663
 prenatal developmental effects, 664–665
 reward, tolerance and dependence
 mechanisms, 675–676
 synthesis and metabolism, 663–664
 future research on, 676
 pharmacology
 appetite regulation, 670–672
 cognitive function, 669–670
 emesis, 673–674
 endocannabinoid system physiology,
 665–666
 neurotoxicity, 672–673
 overview, 659–662
 pain management, 666–669
- Mast cells
 calcitonin gene-related peptide sites
 and migraine therapy targeting,
 762
- MATRICES program
 schizophrenia-related cognitive
 dysfunction, 254–255
- Mazindol
 psychostimulant abuse therapy, 587
- mCCP serotonin receptor agonist
 obsessive-compulsive disorders, 234
- Mecamylamine
 nicotine dependence and withdrawal
 therapy, 549
- Medial prefrontal cortex (MPFC)
 anxiety neurobiology
 brain imaging studies, 15
- Melanocyte-inhibiting factor (MIF) peptides
 pain management and
- Memantine
 schizophrenia pharmacotherapy, 392
- Memory deficits
 cannabinoid receptors and, 669–670
 3,4-methylenedioxymethamphetamine
 and, 630–631
 schizophrenia
 animal models, 263
 schizophrenia and, 254–255
- Mesoaccumbens system
 alcohol abuse studies
 dopaminergic receptor systems and
 substrates, 472–473
 GABA_A benzodiazepine receptor
 complex
 site-specific microinjection
 techniques, 494–496
- Mesolimbic pathway
 alcohol abuse studies
 dopaminergic receptor systems and
 substrates, 472–473
 psychostimulant abuse
 dopamine system, 574–575
- Mesopallidal system
 alcohol abuse studies, 476–480
- Metabolic syndrome
 antipsychotics and, 254
- Metabolism kinetics
 endocannabinoid system, 663–664
 3,4-methylenedioxymethamphetamine
 neurotoxicity and, 621–622
 nicotine dependence and withdrawal,
 544–545

- Metabolites
 3,4-methylenedioxymethamphetamine
 neurotoxicity and mechanisms of,
 621–622
- Metabotropic glutamate receptors
 atypical antipsychotics, 427–429
 glutamate theory of schizophrenia,
 293–294
 history of, 290–291
 pathological evidence, 292
 psychostimulant abuse, 576
 schizophrenia pharmacotherapy
 group II receptor targeting, 391–392
- Methadone
 heroin addiction pharmacotherapy
 history of, 453–457
 in "office-based practice," 700
 opiate addiction therapy
 buprenorphine comparisons with,
 697–698
 psychostimulant abuse therapy, 585–586
 treatment statistics, 694–696
- Methamphetamine. *See also* 3,4-Methylene-
 dioxymethamphetamine (MDMA)
 3,4-methylenedioxymethamphetamine
 and
 behavioral effects, 630–631
 monoamine neuropharmacology, 571–575
- α -Methylparatyrosine (AMPT)
 schizophrenia dopamine hypothesis,
 372–373
 schizophrenia therapy
 D₂ receptor occupancy and effect,
 376–378
- Methylation techniques
 3,4-methylenedioxymethamphetamine
 neurotoxicity and, 622
- 3,4-Methylenedioxyamphetamine (MDA)
 3,4-methylenedioxymethamphetamine
 neurotoxicity and, 621–622
- 3,4-Methylenedioxymethamphetamine
 (MDMA)
 behavioral effects, 618–619
 body temperature effects, 617–618
 brain biochemistry and function, 631–632
 monoamine release, 616
 neuroendocrine and immune responses,
 618
 neurotoxicity, 619–628
 animal models, 620–621
 cytokines and microglia, 627–628
 hyperthermia, 624–625
 long-term neurochemical change,
 619–620
 metabolite mechanisms, 621–622
 monoaminergic transporter, 625–627
 oxidative stress, 623–624
 neurotoxic lesions
 behavioral effects, 629–631
 thermoregulation effects, 629
 neurotransmitter receptors and
 transporters, 617
 overview, 614
 reinforcing properties, 614–616
 tryptophan hydroxylase, 616–617
- Methylphenidate
 chronic exposure and sensitization effects,
 580–585
 monoamine neuropharmacology, 571–575
 psychostimulant abuse therapy, 587
- Microglia
 3,4-methylenedioxymethamphetamine
 effects on, 627–628
- Microinjection studies
 alcohol abuse
 GABA_A benzodiazepine receptor
 complex modulation, 505–507
- Migraine headaches
 history and definition, 758–759
 therapy
 calcitonin gene-related peptide and,
 759–763
 injection techniques, 763
 neurovascular model, 759–760
 receptor antagonist therapeutic
 efficacy, 763–764
 synthesis and actions, 760–761
 trigeminovascular sites, 761–763
 future trends in, 768–769
 history of, 758–759
 migraine diagnostic criteria, 758–759
 overview, 758
 pharmacology, 764–768
 acute therapy, 764–765
 preventive therapy, 766–768
- Mild mental stress models
 neurosteroid effects, 151–152
- Mineralocorticoid receptors
 psychostimulant abuse, 577–578
- Mirrored chamber
 mouse anxiety models
 neurosteroid effects, 147–148
- Mirtazapine
 anxiety disorder therapy, 70

- Missense mutations
 PRODH gene
 schizophrenia molecular genetics, 329–330
- Mitogen-activated protein kinase
 transient receptor potential V1 (TRPV1)
 receptor expression, 729
- Mitotic inhibitor methylazoxymethanol (MAM)
 in schizophrenia, 265
- Moclobemide
 anxiety disorder therapy, 70
- Modafinil
 psychostimulant abuse therapy, 588
 schizophrenia therapy, 389
- Modified forced-swim test
 animal anxiety models
 neurosteroid effects, 150–151
- Modulation therapy
 addictive disorders, 458–459
- Molecular genetics
 corticotropin-releasing factor receptor antagonists
 ligand binding mechanisms, 191–195
 GABA_A benzodiazepine receptor complex
 alcohol abuse studies, 487–501
 alcohol/modulator commonalities, 487–488
 CA1/CA3 hippocampus, 511–516
 efficacy of β CCT/3PBD modulation, GABA_{A1,2,3,5} receptors, 499–501
 future research issues, 517–518
 GABA-DA interaction hypothesis, 496–498
 ligand selectivity with GABA_{A1} subunits, 498–499
 microinjection studies, 505–506
 naltrexone antagonist, 507–511
 novel CNS GABAergic substrates, 498
 oral administration, β CCT/3PBD
 anxiety reduction, 510–511
 vs. naltrexone, 507–511
 probe applications, 488–493
 site-specific microinjection, 493–496
 subunit selectivity vs. intrinsic efficacy, 516–517
 systemic administration, 492–493, 503–504
 ventral pallidum, 501–502
 schizophrenia, 323–325
 candidate genes, 325–328
 chromosomal abnormalities, 328–331
 functional candidate genes, 331–332
 future research issues, 333
 gene linkage studies, 323–324
 neurochemistry and, 261–262
 positional candidate genes, 325
 susceptibility genes, 351–355
 DISC1 gene, 351–352
 DTNBP1 gene, 352–353
 function, 332–333
 NRG1 gene, 353–355
- Molecular path model
 benzodiazepine activity, 115
- Molecular targeting
 schizophrenia-related cognitive dysfunction therapy, 254–255
- Monoamine neurotransmitters
 anxiety disorder anxiolytics, 63–72
 antidepressants, 64–70
 antipsychotics, 71–72
 beta blockers, 71
 cannabinoid analgesics and, 668–669
 dopamine hypothesis of schizophrenia, 371–373
 3,4-methylenedioxymethamphetamine effects, 616
 psychostimulant abuse and, 569–575
- Monoamine oxidase inhibitors (MAOIs)
 anxiety disorder therapy, 70
 obsessive-compulsive disorders
 metabolism studies, 223
 schizophrenia therapy, 394
- Monoaminergic transporter
 3,4-methylenedioxymethamphetamine neurotoxicity and, 625–627
- Monotherapies
 obsessive-compulsive disorders
 controlled trials, 225
- MOR-1 opioid receptor
 pain management and, 716–717
 structure and function, 748–751
- Morphine compounds
 mu opioid receptors and, 748–751
 obsessive-compulsive disorder therapy, 234
 peripheral-central interactions, 719–721
 spinal-supraspinal interactions, 718–720
- Mouse studies
 anxiety neurobiology
 anxiety-like behavior, genetically altered mice, 19–24

- neuroticism (N trait), 6–9
- oligogenic anxiety-like conditions, 32–33
- QTL studies, 19
- benzodiazepine functional diversity, 112–114
- MPEP antagonist
 - psychostimulant abuse and, 576
- Multipoint linkage analysis
 - anxiety neurobiology, 4
- Mu opioid receptors
 - obsessive-compulsive disorders, 234
 - psychostimulant abuse and, 578–579
 - structure and function, 748–751
- Muscarinic receptor agonists
 - atypical antipsychotics and cholinergic agents, 429–430
 - schizophrenia therapy, 393–394
- Muscimol
 - alcohol abuse studies
 - GABA_A benzodiazepine receptor complex manipulation, 494–496
- Naloxone
 - nicotine dependence and withdrawal, 540
 - opiate addiction therapy
 - regulatory studies, 696–697
- Naltrexone
 - alcohol abuse studies
 - oral administration of β CCT/3PBC vs., 507–511
 - nicotine dependence and withdrawal, 540
 - pharmacotherapy, 550–551
 - opiate addiction therapy, 698–699
 - psychostimulant abuse therapy, 585–586
- NAN-190 antagonists
 - nicotine dependence and withdrawal
 - withdrawal substrate specificity, 542–543
- N-back task analysis
 - schizophrenia cognitive dysfunction and, 259
- NDMC metabolite
 - cholinergic mechanisms and, 429–430
- N-domain fragments
 - corticotropin-releasing factor receptor antagonists
 - ligand binding mechanisms, 192–195
- Negative affect
 - in schizophrenia, 255–256
 - neural network studies, 258–259
- NEO-five factor inventory (NEO-FFI)
 - anxiety neurobiology
 - genetic susceptibility studies, 18–19
- NEO personality inventory
 - anxiety neurobiology, 5–6
 - human personality traits, 9–12
- Neospinothalamic pain pathways
 - classification of, 711–714
- Nerve-growth factor (NGF)
 - transient receptor potential VI (TRPV1)
 - receptor expression, 729
- Neural networks
 - glutamate theory of schizophrenia
 - history of, 290–291
 - schizophrenia
 - cognitive dysfunction and, 259
 - future research issues, 266
 - negative affect and, 255–256, 258–259
 - psychosis and, 257–258
- Neuregulin I (NRG1)
 - schizophrenia candidate gene, 326–327
 - ErbB3 receptor, 328
 - functional implications, 332–333
 - molecular interactions, 352–353
 - susceptibility identification, 350
- Neuroactive steroids
 - anxiety disorders
 - alcohol effects, 157–159
 - animal models, 142–152
 - behavioral effects, 142
 - brain and peripheral sources, 135–137
 - chemistry and pharmacology, 135–142
 - enantiomeric selectivity, 141–142
 - GABA_A receptors and ligand-gated ion channels, 137–141
 - HPA axis function, 154–156
 - overview, 134–135
 - stress-induced behaviors
 - drug abuse relapse, 159–160
 - HPA axis, 153–154
 - overview, 152–153
- Neuroanatomical controls
 - alcohol abuse studies in alcohol-preferring rats, 469–470
- Neurobiology
 - obsessive-compulsive disorders, 216–224
 - brain imaging studies, 217–222
 - functional imaging studies, 219–220
 - magnetic resonance spectroscopy, 220

- Neurochemistry
 - 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity
 - long-term changes in, 619–620
 - schizophrenia, 260–262
 - hypotheses, 371–376
 - dopamine hypothesis, 371–373
 - glutamate receptor hypothesis, 373–374
 - integrated dopamine/glutamate hypotheses, 374–376
- Neurodevelopmental animal model
 - schizophrenia, 265
- Neuroendocrine systems
 - 3,4-methylenedioxymethamphetamine effects on, 618
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 580–585
- Neurogenesis
 - atypical antipsychotics and, 430
 - schizophrenia
 - disruption of, 265
- Neurogenic inflammation
 - vanilloid receptors and, 728–729
- Neuroimaging studies
 - 3,4-methylenedioxymethamphetamine neurotoxicity
 - brain biochemical and functional changes, 631–632
 - obsessive-compulsive disorders, 219–220
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 582–585
 - monoamine neuropharmacology, 573–575
- Neurokinin 3 receptors
 - antipsychotic mechanisms with, 430
- Neurokinin antagonists
 - schizophrenia therapy, 391
- Neuronal cell adhesion molecules (NCAM)
 - anxiety neurobiology, 30
- Neuronal pathways
 - anxiety neurobiology and, 15–18
 - knockout mice studies, 24–26
 - mouse studies, 19–20
 - pain management
 - anatomical drug interactions, 718–720
 - descending modulatory pathways, 712–714
 - neospinothalamic/paleospinothalamic pathways, 711–712
 - overview, 709–710
- Neuronal systems and substrates
 - calcitonin gene-related peptide sites and migraine therapy targeting, 762
 - dopaminergic receptors
 - alcohol abuse studies, 471–486
 - bed nucleus of stria terminalis, 473–475
 - dopaminergic regulation, early research, 472–473
 - extracellular dopamine, 485–486
 - future research issues, 517–518
 - GABAergic interactions with, 486
 - lateral hypothalamus, 481–485
 - D₂ dopaminergic regulation, hypothesized mechanisms, 481–485
 - ventral pallidum, 476–480
 - dopaminergic regulation hypothesized mechanisms, 478–480
 - nicotine dependence and withdrawal
 - nicotine reinforcement substrates, 537–540
 - withdrawal neurosubstrates, 541–543
- Neuropeptide FF
 - pain management and, 716–717
- Neuropeptides
 - anxiety neurobiology, 16–17
 - psychostimulant abuse and, 578–579
- Neuropeptide Y (NPY)
 - alcohol abuse studies
 - in alcohol-preferring rats, 471
 - anxiety neurobiology and, 17
 - knockout mice studies, 25–26
- Neuropharmacology
 - obsessive-compulsive disorders, 225–235
 - antipsychotic agents, 229–234
 - augmenting agents, 225, 229–234
 - brain imaging studies, 220–222
 - current trials, 234
 - monotherapy trials, 225
 - serotonin uptake inhibitor efficacy, 226–228
 - schizophrenia dopamine hypothesis, 287
- Neuroprotective agents
 - 3,4-methylenedioxymethamphetamine neurotoxicity and, 625
- Neuroreceptor imaging
 - schizophrenia, 259–260

- Neurosteroids
schizophrenia therapy, 394
- Neurosurgery
obsessive-compulsive disorders, 235–237
- Neurotensin agonist/antagonist
psychostimulant abuse and, 579
schizophrenia therapy, 390
- Neuroticism (N trait)
anxiety neurobiology, 5–6
mouse behavior, 6–9
- Neurotoxicity
cannabinoid receptors and, 672–673
3,4-Methylenedioxyamphetamine (MDMA), 619–628
animal models, 620–621
cytokines and microglia, 627–628
hyperthermia, 624–625
long-term neurochemical change, 619–620
metabolite mechanisms, 621–622
monoaminergic transporter, 625–627
oxidative stress, 623–624
- Neurotransmitters. *See also* specific
Neurotransmitters
addictive disorders
modulator therapy and, 458–459
anxiety neurobiology
knockout mice studies, 24–26
anxiety neurobiology and, 15–18
endocannabinoid system, 663
3,4-methylenedioxyamphetamine effects on
receptor/transporter effects, 617
obsessive-compulsive disorders
metabolism studies, 223
pain neuropharmacology, 714–717
drug action localization, 718
psychostimulant abuse
chronic exposure and sensitization effects, 580–581, 583–585
- Neurovascular model
migraine therapy, calcitonin gene-related peptide, 759–760
- NF- κ B transcription factor family
anxiety neurobiology and, 31
- Nicotine
basic properties, 535–536
patches
obsessive-compulsive disorder therapy, 234
pharmacology, 536–545
absorption pharmacokinetics, 543–544
dependence and withdrawal therapy
bupropion, 549–550
cannabinoid antagonists, 550
nicotinic antagonists, 548–549
nicotinic partial agonists, 548
nonnicotinic agents, 549–551
opioid antagonists, 550–551
overview, 545–546
public health policy and, 551–552
replacement medications, 546–548
tricyclic antidepressants, 550
distribution pharmacokinetics, 544
metabolism and elimination
pharmacokinetics, 544–545
nicotine reinforcement neurosubstrates, 537–540
nicotinic acetylcholine receptors, 537
functional adaptations, 540–541
withdrawal neurosubstrates, 541–543
- Nicotine gum
nicotine dependence and withdrawal therapy, 547–548
- Nicotine-*N*-oxide
nicotine dependence and withdrawal
metabolism and elimination
pharmacokinetics, 544–545
- Nicotinic acetylcholine receptors (nAChRs)
nicotine dependence and withdrawal
classification and function, 537
functional adaptations mechanisms, 540–541
nicotine reinforcement substrates, 538–540
nicotinic partial agonist therapy, 548
nicotinic partial antagonist therapy, 548–549
overview, 536–537
withdrawal substrates, 542–543
NRG1 molecular interaction, 354–355
schizophrenia pharmacotherapy
cholinergic agents, 393–394
- Nicotinic agonists
anxiety neurobiology and
receptor deficits and, 29–30
- Nicotinic antagonists
nicotine dependence and withdrawal therapy, 548
- Nicotinic partial agonists
nicotine dependence and withdrawal therapy, 548

- Nitric oxide synthase (NOS) inhibitor
3,4-methylenedioxymethamphetamine
neurotoxicity, 623–624
- Nitrogen ohne radikal (NOR) metabolites
benzodiazepine receptor ligand
metabolism, 102
- NMDA (*N*-methyl-D-aspartic acid)
receptors
addictive disorder pharmacotherapy
methadone interactions, 456–457
consolidated glutamate/dopamine
hypotheses, 295–296
glutamate theory of schizophrenia
history of, 289–290
imaging studies, 293
neurochemistry of, 373–374
pathological evidence, 291–292
pharmacological evidence, 294–295
ketamine effects on, 636–637
obsessive-compulsive disorders
glutamate genetic studies, 223
pain management and, 717
schizophrenia pharmacotherapy
first- and second-generation
antipsychotics, 381
targeted drug development for, 391–392
schizophrenia psychosis, 257–258
- Nociception
defined, 710
drug action localization, 718
pain pathways and, 711–712
transient receptor potential V2 (TRPV2),
736–737
- Nonopioid analgesics
migraine management, 765
- Nonpeptide ligands
corticotropin-releasing factor receptor
antagonists, 195–196
- Nonpharmacological therapy
obsessive-compulsive disorders and,
235–237
- Nonsteroidal anti-inflammatory drugs
migraine management, 765, 768
- Noradrenergic systems
psychostimulant abuse
chronic exposure and sensitization
effects, 584
schizophrenia pharmacotherapy, 393
- Norepinephrine (NE)
alcohol abuse studies
dopaminergic receptor systems and
substrates, 472–473
anxiety neurobiology, 15–17
3,4-methylenedioxymethamphetamine
effects on, 616
receptor/transporter effects, 617
psychostimulant abuse
chronic exposure and sensitization
effects, 584
neuropharmacology, 570–575
schizophrenia pharmacotherapy
noradrenergic agent development, 393
- Norepinephrine transporter (NET)
anxiety neurobiology and
knockout mice studies, 24–26
- Nucleus accumbens (NAcc)
alcohol abuse studies
in alcohol-preferring rats, 470–471
dopaminergic receptor systems and
substrates, 471–472
GABA_A benzodiazepine receptor
complex manipulation
site-specific microinjection studies,
493–496
3,4-methylenedioxymethamphetamine
(MDMA)
reinforcing properties, 614–616
- NUDEL gene
DISC1 schizophrenia candidate gene
molecular interactions, 351–352
- Nur transcription factors
schizophrenia therapy
dopamine neurotransmission and,
422
- Obsessive-compulsive disorders (OCD)
animal models, 224
brain regions related to, 13–15
clinical psychopharmacology, 225–235
antipsychotic agents, 229–234
augmenting agents, 225, 229–234
current trials, 234
monotherapy trials, 225
serotonin uptake inhibitor efficacy,
226–228
deep brain stimulation, 236–237
defined, 216
diagnostic criteria, 10–12, 216
genetic studies, 222–224
developmental genes, 223–224
dopamine, 223
glutamate, 223
neurotransmitter metabolism, 223
serotonin, 222–224

- immunomodulatory treatments, 235
- neurobiology, 216–224
 - brain imaging studies, 217–222
 - functional imaging studies, 219–220
 - magnetic resonance spectroscopy, 220
- neuropharmacology
 - brain imaging studies, 220–222
- neurosurgery, 235–237
- nonpharmacological experimental treatments, 235–237
- pharmacotherapy, 77–78
- serotonin/noradrenaline reuptake inhibitors, 69
- summary of therapeutic advances, 237
- symptom induction, 234
- transcranial magnetic stimulation, 236
- tricyclic antidepressants, 69–70
- Ocapridone
 - schizophrenia therapy, 389
- 8-OH-DPAT
 - nicotine dependence and withdrawal withdrawal substrate specificity, 542–543
 - serotonin receptors 5-HT_{2A}-5-HT_{2C} interactions, 422–424
- Olanzapine
 - D₂ receptor blockade, 414–415
 - neurogenesis and, 430
 - schizophrenia therapy
 - brain-derived neurotrophic factor and, 421–422
 - clinical profile, 383–387
 - D₂ receptor occupancy and effect, 376–378
 - safety and tolerability, 388–389
 - serotonin receptor 5-HT_{2A}, 420–421
- Oligogenic anxiety-like conditions
 - anxiety neurobiology
 - mouse studies, 32–33
- Open-field activity
 - mouse anxiety models
 - neurosteroid effects, 148–149
- Opiates
 - addiction and
 - buprenorphine studies, 696–698
 - drug discovery survey, 699–700
 - epidemiology, 691–694
 - future research issues, 698–699
 - treatment statistics, 694–696
 - pain management
 - anatomical interactions, 718–720
- Opioid agonists/antagonists
 - migraine management, 765
 - nicotine dependence and withdrawal therapy, 550–551
- Opioid receptor system
 - addictive disorders
 - reward therapy and, 458–459
 - alcohol abuse studies
 - oral administration of β CCT/3PBC vs. agonists, 507–511
 - delta receptors, 751
 - dimerization, 752
 - endogenous opioids, 746–748
 - future research on, 752
 - kappa receptors, 751–752
 - mu receptors, 748–751
 - nicotine dependence and withdrawal, 540
 - withdrawal substrate specificity, 543
 - orphanin FQ/nociceptin and receptor, 752
 - overview, 745–746
 - pain management and, 716–717
 - targeting mechanisms, 718
 - psychostimulant abuse and, 578–579
 - chronic exposure and sensitization effects, 584
 - short-acting
 - addiction pharmacotherapy and, 453–457
- Orbitofrontal-dorsomedial thalamic loop
 - obsessive-compulsive disorders
 - neuropharmacology, 221–222
- Orphanin FQ/nociceptin (OFQ/N) receptor
 - anxiety neurobiology and
 - knockout mice studies, 25–26
 - structure and function, 748, 752
- Oxidative stress
 - 3,4-methylenedioxymethamphetamine
 - neurotoxicity and, 623–624
- Oxycodone
 - abuse of
 - incidence and prevalence, 692–694
- Pain perception and management
 - calcitonin gene-related peptide for, 768–769
 - marijuana and, 666–668
 - neuronal pathways
 - descending modulatory pathways, 712–714
 - neospinothalamic/paleospinothalamic pathways, 711–712
 - overview, 709–710

- neuropharmacology, 714–717
 - anatomically-based interactions, 718–721
 - drug targeting mechanisms, 718
- transient receptor potential V1 (TRPV1) receptors
 - antagonists, 733
 - capsaicin, protons, and heat, 730–732
 - chemical activators, 732–733
 - cloning of, 728–729
 - desensitization, 735–736
 - expression, 729
 - knockout mouse models, 736
 - nociception channels, 736–737
 - sensitization, 733–735
- Paleospinothalamic pain pathways
 - classification of, 711–712
- Paliperidone
 - schizophrenia therapy, 389
- Panic disorders
 - anticonvulsant therapy, 74–75
 - anxiety disorder therapy, 78
 - brain regions related to, 13–15
 - diagnostic criteria, 10–12
 - neuroactive steroids, 155
- Peptide ligands
 - corticotropin-releasing factor receptor antagonists
 - basic properties, 180–181
 - CRF₁/CRF₂ binding mechanisms, 190–195
 - CRF₁/CRF₂ pharmacology, 185–195
 - CRF₁/CRF₂ receptor pharmacology, 185–195
 - structure and function, 179–185
 - subtypes and distribution, 181–185
- Periaqueductal gray (PAG) stimulation
 - cannabinoid analgesics and, 667–668
- Peripheral benzodiazepine receptors (PBRs)
 - stress-induced behavior
 - neuroactive steroids, 155–156
- Personality traits
 - continuous expression
 - anxiety neurobiology, 9–12
- Pharmacophore models
 - benzodiazepine activity, 116
- Pharmacotherapy
 - addictive disorders
 - history of, 451–457
 - reward modulation/countermodulation and, 458–459
 - risk factors for addiction development, 457–458
- anxiety disorders
 - anxiolytic drugs, 62–75
 - amino acid neurotransmission, 72–75
 - anticonvulsants, 74–75
 - antidepressants, 64–70
 - antihistamines, 75
 - antipsychotics, 71–72
 - benzodiazepines, 73–74
 - beta-blockers, 71
 - lithium, 75
 - monoamine neurotransmission, 63–72
 - serotonin receptor agonists, 70–71
 - depressive disorders, 80
 - future research issues, 81
 - generalized anxiety disorder, 77
 - obsessive-compulsive disorder, 77–78
 - overview, 60
 - panic disorder/agoraphobia, 78
 - phobias, 78, 80
 - posttraumatic stress disorder, 79
 - social anxiety disorder, 79–80
 - treatments chart, 76
- obsessive-compulsive disorders
 - overview, 216
- schizophrenia
 - antipsychotic drug profiles
 - first-generation (conventional) agents, 383
 - safety and tolerability, 387–388
 - second-generation (atypical) agents, 383–387
 - antipsychotic mechanisms of action, 376–382
 - D₁ receptors, 380–381
 - D₂/D₃ and D₄ antagonism and regional specificity, 380
 - D₂ occupancy thresholds and rapid dissociation, 378–380
 - D₂ receptor occupancy, 376–378
 - dopamine release, 381
 - NMDA receptor function, 381
 - synthesis reactions, 381–382
 - current developments and future directions, 388–394
 - cannabinoid hypothesis, 394
 - cholinergic agents, 393–394
 - D₁ agonists and antagonists, 390
 - D₃ antagonists, 390
 - D₄ antagonists, 390

- dopamine system targeting, 389
- glutamate system targeting, 391–393
- neurokinin antagonists, 391
- neurosteroids, 394
- neurotensin agonist/antagonist, 390
- noradrenergic agents, 393
- future research issues, 394–395
- high 5-HT_{2A} vs. D₂ affinity, 378
- neurochemical hypotheses, 371–376
- overview, 370–371
- Phencyclidine. *See also* Ketamine
 - glutamate theory of schizophrenia
 - history of, 289–290
 - neurochemistry of, 374
 - ketamine derivative, 636–637
 - schizophrenia neurochemistry and, 260–262
- Phenothiazines
 - schizophrenia therapy
 - clinical profiles, 383
- Phenotype analysis
 - obsessive-compulsive disorders, 237
 - schizophrenia, 262–263
 - genetic epidemiology, 322–323
- Phenylalkylamines, 637–640
 - addiction, 639–640
 - mechanism of action, 638–639
 - pharmacology, 638
- α -Phenyl-*N*-*tert*-butyl nitron (PBN)
 - 3,4-methylenedioxyamphetamine
 - neurotoxicity
 - oxidative stress, 623–624
- Phobias
 - brain regions related to, 13–15
 - pharmacotherapy, 79–80
- Phosphoinositol 3-kinase-AKT signaling pathway
 - dystrobrevin binding protein 1 (DTNBP1)
 - molecular interactions, 353
- Phosphoinositol-4,5-bisphosphate (PIP₂)
 - transient receptor potential V1 (TRPV1)
 - receptor sensitization, 734–735
- Phospholipase C
 - transient receptor potential V1 (TRPV1)
 - receptor sensitization, 734–735
- Phosphorus MRS
 - schizophrenia analysis, 257
- Picrotoxin
 - alcohol abuse studies
 - GABA_A benzodiazepine receptor complex, 487–488
 - GABAergic modification of dopamine agonists, 496–497
- p-MPPI receptor antagonist
 - nicotine dependence and withdrawal
 - withdrawal substrate specificity, 542–543
- Positional candidate genes
 - schizophrenia genetics, 325
- Positional cloning
 - schizophrenia genetics, 324
- Positron emission tomography (PET)
 - obsessive-compulsive disorders, 219–220
 - schizophrenia
 - dopamine hypothesis, 286
 - schizophrenia analysis, 257
- Postmortem studies
 - schizophrenia, 260–262
 - dopamine hypothesis and, 285
 - future research issues, 355–356
 - overview, 343–344
 - susceptibility gene identification, 344–351
 - susceptibility gene interactions, 351–355
- Postpartum depression
 - neuroactive steroids, 156–157
- Posttraumatic stress disorder (PTSD)
 - anticonvulsant therapy, 74–75
 - brain regions related to, 13–15
 - diagnostic criteria, 10–12
 - mirtazapine therapy, 70
 - neuroactive steroids, 154–155
 - pharmacotherapy, 79
- PPP3CC gene
 - schizophrenia molecular genetics, 328
- P rat line. *See* Alcohol-preferring rats
- Predictive validity
 - animal anxiety-like behavior and, 12
- "Preemptive analgesia"
 - pain management and, 717
- Prefrontal cortex (PFC)
 - integrated glutamate/dopamine
 - hypotheses of schizophrenia, 374–376
- Pregnancy
 - marijuana effects in, 664–665
 - 3,4-methylenedioxyamphetamine and, 630–631
- Pregnenolone sulfate (PREGS)
 - in brain, 137
- Prenatal development
 - marijuana effects on, 664–665

- Prescription drugs. *See also* Opiates
 abuse of
 incidence and prevalence, 692–694
- Preventive therapy
 migraine management, 766–768
- PRODH gene
 schizophrenia molecular genetics, 329–330
- Prodromal period
 schizophrenia therapy
 second-generation antipsychotics,
 386–387
- Progesterone levels
 depression
 neuroactive steroids, 156–157
- Pro-opiomelanocortin peptide group
 nicotine dependence and withdrawal, 540
- 3-Propoxy- β -carboline hydrochloride
 (3BPC)
 alcohol abuse studies
 anxiety reduction with, 510–511
 GABA_{A1,2,3,5} receptor subunit
 modulation, 499–501
 GABA_{A1} receptor subunit selectivity,
 498–499
 microinjection techniques, 505–507
 oral administration, 507–511
 systemic administration, 503–504
- Protein kinase A
 transient receptor potential V1 (TRPV1)
 receptor sensitization, 733–735
- Protein kinase C
 transient receptor potential V1 (TRPV1)
 receptor sensitization, 733–735
- Protein kinase C _{γ}
 anxiety neurobiology and, 31
- Protons
 transient receptor potential V1 (TRPV1)
 receptor expression, 730–732
- Psilocybin
 schizophrenia therapy
 serotonin receptor 5-HT_{2A}, 420–421
- Psychoeducation
 anxiety management with, 60–61
- Psychological traits
 anxiety neurobiology
 continuous expression of normal
 personality, 9–10
 genetic basis of, 4–6
 mouse behavior extrapolation studies,
 6–9
- Psychosis
 in schizophrenia, 253–254
 animal models, 264–265
 neural network studies, 257–258
 second-generation antipsychotics and,
 386–387
- Psychostimulants
 abuse-related neuropharmacology,
 569–579
 γ -aminobutyric acid, 576–577
 glutamate, 575–576
 hypothalamic-pituitary-adrenal axis,
 577–578
 monoamines, 570–575
 neuropeptides, 578–579
 addiction therapy development,
 585–586
 chronic exposure-related neurobiology,
 579–589
 neurotransmitter/neuroendocrine
 systems, 580–584
 signal transduction mechanisms and
 gene expression, 584–585
 future research issues, 588–589
 therapeutic applications of, 567–569
- Public health policy
 nicotine dependency and withdrawal
 therapy, 551–552
- Pyrazolopyrimidine
 corticotropin-releasing factor receptor
 antagonists
 anxiety/depression therapeutic
 potential, 197–198
- Pyrazoloquinoline
 alcohol abuse studies
 GABA_A benzodiazepine receptor
 complex, 490–493
- Quantitative behavioral genetics
 anxiety neurobiology, 6
- Quantitative trait locus (QTL) analysis
 anxiety neurobiology, 4
 emotionality studies in mice, 8–9
 mice studies, 19
 oligogenic anxiety-like conditions,
 32–33
- Quetiapine
 schizophrenia therapy
 clinical profile, 383–387
 safety and tolerability, 389
- Quinelorane
 alcohol abuse studies
 dopaminergic receptor systems and
 substrates, 472–473

- Quinpirole
 alcohol abuse studies
 dopaminergic receptor systems and substrates, 472–473
- Raclopride
 alcohol abuse studies
 dopaminergic receptor systems and substrates, 472–473
 chronic exposure and sensitization effects, 582–585
- ¹¹C-Raclopride
 striatal D₂ receptor blockade, 414–415
- Radiolabeled peptides
 corticotropin-releasing factor receptor antagonists
 peptide ligand pharmacology, 187–195
- Rapid dissociation
 schizophrenia pharmacotherapy
 D₂ receptor occupancy thresholds, 379–380
- Receptor activity modifying protein 1 (RAMP1)
 calcitonin gene-related peptide sites and migraine therapy targeting, 762
- Receptor density assessment
 schizophrenia
 dopamine hypothesis and, 285
 schizophrenia neuroreceptor imaging, 259–260
- Receptor ligand pharmacology
 benzodiazepines, 97–102
 endogenous site, 98–99
 metabolism functions, 101–102
 single-cell GABA response modulation, 99–100
 therapeutic action, 97–98
 tolerance and dependence characteristics, 100–101
- Regional cerebral blood flow (rCBF)
 schizophrenia, 257–259
- Regional specificity
 schizophrenia therapy
 D₂/D₃ and D₄ receptor antagonism and, 380
- "Region-specific" neuroanatomical controls
 alcohol abuse studies in alcohol-preferring rats, 469–470
- Regulator of G-protein signaling 4 (RGS4)
 schizophrenia candidate gene, 328
 susceptibility identification, 351
- Reinforcing mechanisms
 alcohol abuse studies in alcohol-preferring rats, 469
 3,4-methylenedioxymethamphetamine (MDMA), 614–616
- Resiniferatoxin (RTX)
 cloning of, 727–729
 transient receptor potential V1 (TRPV1) receptor expression, 733
- Respiratory system
 γ -hydroxybutyric acid (GHB) effects, 634
- Reuptake inhibitors
 psychostimulant abuse
 monoamine neuropharmacology, 571–575
- Reversible inhibitor of monoamine oxidase A (RIMA)
 anxiety disorder therapy, 70
- Reward effects
 addictive disorders, 458–459
 endocannabinoids and, 675–676
 3,4-methylenedioxymethamphetamine (MDMA), 614–616
 psychostimulant abuse
 chronic exposure and sensitization effects, 581–585
- Rhodopsin
 corticotropin-releasing factor receptor antagonists
 ligand binding mechanisms, 191–195
- Riluzole
 obsessive-compulsive disorder therapy, 234
- Rimonabant
 appetite regulation, 670–672
 cannabinoid receptors and, 661–662
 cognition and, 669–670
 endocannabinoid physiology and, 665–675
 nicotine dependence and withdrawal therapy, 550
 opiate dependence therapy and, 699
 pain management and, 667–668
 reward, tolerance, and dependence, 675–676
- Risperidone
 neurogenesis and, 430
 schizophrenia therapy
 clinical profile, 383–387
 safety and tolerability, 389
 serotonin receptor 5-HT_{2A}, 418–421

- Ritanserin
3,4-methylenedioxyamphetamine
effects on, 616
- RO19-4603 inverse agonist
alcohol abuse studies
GABA_A benzodiazepine receptor
complex, 488–493
site-specific microinjection
techniques, 494–496
systemic administration studies,
492–493
- Rohypnol. *See* Flunitrazepam
- ROI15-4513 inverse agonist
alcohol abuse studies
GABA_A benzodiazepine receptor
complex
alcohol-modulator commonalities,
487–488
- RU34000 imidazopyrimidine inverse agonist
alcohol abuse studies
GABA_A benzodiazepine receptor
complex, 490–493
site-specific microinjection
techniques, 496
- RY 023 inverse agonist
alcohol abuse studies
GABA_{A5} receptor specificity,
512–516
- Safety
schizophrenia therapy
second-generation antipsychotics,
387–388
- Samson test procedure
alcohol abuse studies in alcohol-preferring
rats, 468–470
- SB-271046
serotonin receptor 5-HT₆ and,
425–426
- SB-399885
serotonin receptor 5-HT₆ and, 426
- SCH 23390 compound
alcohol abuse studies
bed nucleus of stria terminalis system,
475
lateral hypothalamus, effects on,
481–485
ventral pallidum receptor blockade,
477–480
- Schizophrenia
animal models, 263–265
biological mechanisms, 256–263
brain imaging studies, 256–260
characteristics of, 252
clinical phenomenology and treatment,
252–256
cognitive dysfunction, 254–255
dopamine hypothesis
cortical vs. striatal dopamine, 287–289
genetic evidence, 286–287
history, 284–285
imaging evidence, 285–286
pathological evidence, 285
pharmacological evidence, 287
pharmacotherapy, 371–373
evolution of theories on, 283–284
future research issues, 265–266
genetic epidemiology, 321–323
phenotype definition, 322–323
genetics and phenotypes, 262–263
glutamate theory of
genetic evidence for, 293–294
history, 289–291
imaging evidence for, 292–293
pathological evidence for, 291–292
pharmacological evidence for,
294–295
pharmacotherapy, 373–374
integrated glutamate/dopamine
hypotheses, 295–297
pharmacotherapy, 374–376
molecular genetics, 323–325
candidate genes, 325–328
chromosomal abnormalities, 328–331
functional candidate genes, 331–332
future research issues, 333
susceptibility gene function, 332–333
negative affect, 255–256
neural network studies and, 255–259
neurochemistry, 260–262
neurogenesis in, 430
neuroreceptor imaging, 259–260
pharmacotherapy
antipsychotic drug profiles
first-generation (conventional)
agents, 383
safety and tolerability, 387–388
second-generation (atypical) agents,
383–387
antipsychotic mechanisms of action,
376–382
D₁ receptors, 380–381
D₂/D₃ and D₄ antagonism and
regional specificity, 380

- D₂ occupancy thresholds and rapid dissociation, 378–380
- D₂ receptor occupancy, 376–378
- dopamine release, 381
- NMDA receptor function, 381
- synthesis reactions, 381–382
- current developments and future directions, 388–394
- cannabinoid hypothesis, 394
- cholinergic agents, 393–394
- D₁ agonists and antagonists, 390
- D₃ antagonists, 390
- D₄ antagonists, 390
- dopamine system targeting, 389
- glutamate system targeting, 391–393
- neurokinin antagonists, 391
- neurosteroids, 394
- neurotensin agonist/antagonist, 390
- noradrenergic agents, 393
- future research issues, 394–395
- high 5-HT_{2A} vs. D₂ affinity, 378
- neurochemical hypotheses, 371–376
- overview, 370–371
- postmortem studies, 260–262
- dopamine hypothesis and, 285
- future research issues, 355–356
- overview, 343–344
- susceptibility gene identification, 344–351
- susceptibility gene interactions, 351–355
- prevalence, 252–253
- psychosis and, 253–254
- symptom classification, 253
- Second-generation antipsychotics (SGAs)
- schizophrenia therapy
- clinical profile, 383–387
- D₂/D₃ and D₄ receptor antagonism and regional specificity, 380
- D₂ receptor occupancy thresholds and rapid dissociation, 378–380
- history of, 370–371
- NMDA receptor antagonists, 381
- safety and tolerability, 387–388
- Selective serotonin reuptake inhibitors (SSRIs)
- anxiety disorder therapy, 66–69
- obsessive-compulsive disorders
- controlled trials, 225
- panic disorder therapy, 78
- posttraumatic stress disorder therapy, 79
- social anxiety disorder therapy, 79–80
- Selegiline
- schizophrenia therapy, 394
- Sensitivity
- psychostimulant abuse and reduction of neurobiology of, 579–585
- transient receptor potential V1 (TRPV1) receptor expression, 733–735
- Sensory neurons
- pain pathways, 711–712
- Separation-induced ultrasonic vocalizations
- animal anxiety models
- neurosteroid effects, 150
- Sequence homology
- corticotropin-releasing factor receptor antagonists
- ligand binding mechanisms, 191–195
- Serotonin (5-HT)
- antipsychotic drugs and release of, 426
- anxiety disorder anxiolytics
- monoamine neurotransmission, 63–72
- anxiety neurobiology, 4
- genetic susceptibility studies, 18–19
- neurotransmission mechanisms, 15–17
- 3,4-methylenedioxymethamphetamine
- effects on, 616
- long-term neurochemical effects, 619–620
- oxidative stress, 623–624
- receptor/transporter effects, 617
- nicotine dependence and withdrawal
- withdrawal substrates, 542–543
- obsessive-compulsive disorders
- genetic studies, 222–224
- psychostimulant abuse
- neuropharmacology, 570–575
- Serotonin and noradrenaline reuptake inhibitors (SNRI)
- anxiety disorder therapy, 69
- Serotonin hypothesis
- obsessive-compulsive disorders
- neuropharmacology, 221–222
- Serotonin receptor 5-HT/D₂ hypothesis
- atypical antipsychotics, 417–418
- serotonin receptor 5-HT_{2A}, 419–421
- Serotonin receptors
- atypical antipsychotics
- adrenergic mechanisms, 426–427
- serotonin receptor 5-HT_{1A}-5-HT_{2A} interactions, 421–425
- serotonin receptor 5-HT_{2A}, 418–421
- cortical dopamine efflux and cognitive function, 421–422
- extrapyramidal function, 422

- serotonin receptor 5-HT_{2A}-5-HT_{2C} receptor interactions, 422–424
- serotonin receptor 5-HT/D₂ hypothesis, 417–418
- schizophrenia neurochemistry and, 261–262
- schizophrenia pharmacotherapy
 - serotonin receptor 5-HT_{2A} D₂ antagonism and, 381
- serotonin 5-HT_{1A}
 - nicotine dependence and withdrawal, 542–543
- serotonin 5-HT_{2C} receptors
 - psychostimulant abuse, 574–575
- serotonin receptor 5-HT_{1A}
 - anxiety disorder therapy, 70–71
 - anxiety neurobiology and knockout mice deficit studies, 27–30
- serotonin receptor 5-HT_{1B}
 - anxiety neurobiology and knockout mice deficit studies, 28–30
- serotonin receptor 5-HT_{2A}
 - cortical dopamine efflux and cognitive function, 421–422
 - extrapyramidal function, 422
 - LSD downregulation of, 638–640
 - schizophrenia pharmacotherapy
 - D₂ antagonism and, 381
- serotonin receptor 5-HT₆ interactions
 - atypical antipsychotics, 425–426
 - triptan therapy for migraines, 764–765
- Serotonin reuptake inhibitors (SRIs)
 - obsessive-compulsive disorders
 - brain neuropharmacology, 221–222
 - neuropharmacology, 226–228
- Serotonin transporter (5-HTT)
 - anxiety neurobiology
 - environmental effects and, 34–35
 - anxiety neurobiology and knockout mice studies, 24–26
 - 3,4-methylenedioxymethamphetamine neurotoxicity and, 625–627
 - obsessive-compulsive disorders
 - abnormalities, 219–220
 - genetic studies, 222–224
- Serotonin transporter (SERT) antagonists
 - obsessive-compulsive disorders, 223
- Sertindole
 - schizophrenia therapy
 - clinical profile, 383–387
- Signal transduction mechanisms
 - psychostimulant abuse
 - chronic exposure and sensitization effects, 584–585
- Single-nucleotide polymorphisms (SNPs)
 - addictive disorders vulnerability, 457–458
 - catechol-*O*-methyl transferase
 - as schizophrenia susceptibility gene, 347–348
 - schizophrenia genetics
 - DISC1 molecular interactions, 352
 - GRM3 gene, 349
 - positional candidate genes, 325
- Single-photon-emission computerized tomography (SPECT)
 - schizophrenia analysis, 257
- Site-specific microinjection studies
 - alcohol abuse
 - GABA_A benzodiazepine receptor complex manipulation, 493–496
- Smoking. *See* Nicotine
- Social anxiety disorder
 - pharmacotherapy, 79–80
- Social interaction paradigm
 - 3,4-methylenedioxymethamphetamine effects on, 630–631
- Social isolation
 - animal anxiety model
 - neurosteroid effects, 151–152
 - schizophrenia
 - animal models, 264
- Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs)
 - dystrobrevin binding protein 1 (DTNBP1)
 - molecular interactions, 353
- "Speedball" psychostimulant combination
 - neuropeptide pharmacology and, 578–579
- Splice variants
 - corticotropin-releasing factor receptor
 - antagonists
 - receptor subunits, 182–185
- SR48692
 - psychostimulant abuse
 - neuropeptide pharmacology and, 579
- SR144528 antagonist
 - cannabinoid receptors and, 661–662
- Stimulant medications
 - psychostimulant therapy, 587–588
- Stress
 - addictive disorders and response to, 459
 - cannabinoid analgesics and, 667–668
 - neuroactive steroid interactions
 - drug abuse relapse, 159–160

- HPA axis, 153–154
 - overview, 152–153
- psychostimulant abuse
 - chronic exposure and sensitization effects, 580–585
 - neuropharmacology and, 577–578
- Striatal dopamine receptors
 - atypical antipsychotic drugs
 - clozapine D₂ receptor blockade, 414–415
 - schizophrenia dopamine hypothesis and, 287–288
- Structural studies
 - obsessive-compulsive disorders, 217–218
- Structure-activity relationships (SARs)
 - benzodiazepines, 114–116
- Substance P
 - anxiety neurobiology and, 17
- Substantia nigra
 - clozapine D₂ receptor blockade, 414–415
- Sucrose-fading technique
 - alcohol abuse studies in alcohol-preferring rats, 467–470
- Sulfate fraction
 - neuroactive steroids
 - in brain, 137
- Sulpiride
 - alcohol abuse studies
 - dopaminergic receptor systems and substrates, 472–473
 - ventral pallidum receptor blockade, 477–480
- Sumatriptan
 - migraine management with, 764–765
 - obsessive-compulsive disorders, 234
- Susceptibility genes
 - schizophrenia
 - future research issues, 355–356
 - gene linkage studies, 324
 - molecular genetics
 - functional implications, 332–333
 - molecular interactions, 351–355
 - postmortem studies
 - overview, 343–344
 - susceptibility gene identification, 344–351
 - susceptibility gene interactions, 351–355
- Sweetened cocktail solution procedure
 - alcohol abuse studies in alcohol-preferring rats, 468–470
- Synapsin I proteins
 - dystrobrevin binding protein 1 (DTNBP1)
 - molecular interactions, 353
- Synaptosomal-associated protein 25 (SNAP25)
 - dystrobrevin binding protein 1 (DTNBP1)
 - molecular interactions, 353
- Synthesis
 - antipsychotics
 - schizophrenia pharmacotherapy, 381–382
 - endocannabinoid system, 663–664
- Systemic administration studies
 - alcohol abuse studies
 - GABA_A benzodiazepine receptor complex, 492–493
- Systems biology theory
 - schizophrenia and, 255–256
- "Systems neuroscience"
 - schizophrenia dopamine hypothesis and, 288
- T*-butyl agents
 - alcohol abuse studies
 - GABA_A benzodiazepine receptor complex
 - site-specific microinjection techniques, 494–496
- Δ⁹-Tetrahydrocannabinol
 - analgesic properties, 666–669
 - appetite regulation, 670–672
 - cannabinoid receptor binding, 663
 - cognition and, 669–670
 - emesis modulation, 674–675
 - endocannabinoid physiology and, 665–675
 - isolation off, 660–661
 - neurotoxicity effects, 672–673
 - prenatal development and, 664–665
 - reward, tolerance, and dependence, 675–676
- Thermoregulation
 - 3,4-methylenedioxymethamphetamine
 - effects on, 629
- Thioxanthine
 - schizophrenia therapy
 - clinical profile, 383
- THIP agonist
 - alcohol abuse studies
 - GABA_A benzodiazepine receptor complex, 488–493

- Tiagabine
 psychostimulant abuse therapy, 588
- Tissue injury
 transient receptor potential V1 (TRPV1)
 receptor expression, 729–732
- Tolcapone
 schizophrenia therapy, 389
- Tolerability
 schizophrenia therapy
 second-generation antipsychotics,
 387–388
- Tolerance mechanisms
 benzodiazepines, 100
 endocannabinoids, 675–676
 psychostimulant abuse
 neurobiology of, 579–585
- Topiramate
 migraine management, 766
 psychostimulant abuse therapy, 688
- Topological analysis
 corticotropin-releasing factor receptor
 antagonists
 receptor subunits, 183–185
- Tourette's disorder
 obsessive-compulsive disorder
 comorbidity, 216
- Tramadol
 obsessive-compulsive disorder therapy,
 234
- Transcranial magnetic stimulation (TMS)
 obsessive-compulsive disorders, 236
- Transcriptional regulators
 anxiety neurobiology and
 mouse studies, 19, 22
- Transdermal nicotine patch
 mecamylamine in conjunction with, 549
 nicotine dependence and withdrawal
 therapy, 546–547
 obsessive-compulsive disorder therapy, 234
- Transient receptor potential V1 (TRPV1)
 receptors
 analgesic properties, 668–669
 antagonists, 733
 capsaicin, protons, and heat, 730–732
 chemical activators, 732–733
 cloning of, 728–729
 desensitization, 735–736
 endocannabinoid ligands, 664
 expression, 729
 knockout mouse models, 736
 nociception channels, 736–737
 sensitization, 733–735
- Transient receptor potential V2 (TRPV2)
 nociception and, 736–737
- Transient receptor potential V3 (TRPV3)
 nociception and, 737
- Transient receptor potential V4 (TRPV4)
 nociception and, 737
- TRAR4 gene
 schizophrenia molecular genetics, 328
- Treatment Episode Data Set (TEDS)
 opiate treatment statistics, 694–696
- Tricyclic antidepressants (TCAs)
 anxiety disorder therapy, 69–70
 nicotine dependence and withdrawal
 therapy, 550
 panic disorder therapy, 78
 psychostimulant abuse therapy,
 586–587
- Trigeminal ganglion
 migraine therapy targeting of, 760
- Trigeminovascular system
 calcitonin gene-related peptide sites and
 migraine therapy targeting,
 761–762
- Triptans
 migraine management with, 764–765
- Tryptophan hydroxylase
 3,4-methylenedioxymethamphetamine
 effects on, 616–617
- Two-bottle water choice procedure
 alcohol abuse studies in alcohol-preferring
 rats, 468–470
- Tyrosine-hydroxylase
 schizophrenia dopamine hypothesis and,
 288–289
- Tyrosine kinase B (trkB)
 anxiety neurobiology
 receptor deficits and, 29–30
- Urocortins
 corticotropin-releasing factor receptor
 antagonists
 ligand structure, 180–181
- Val66Met substitution polymorphism
 anxiety neurobiology
 genetic susceptibility studies, 18–19
 schizophrenia
 serotonin receptor 5-HT_{2A} receptor
 and, 421–422
- Valproate
 anxiety disorder therapy, 75
 migraine management, 765–766

- Vanilloid receptors
 cloning, 727–729
 transient receptor potential V1 expression, 729
 antagonists, 733
 capsaicin, protons, and heat, 730–732
 chemical activators, 732–733
 desensitization, 735–736
 knockout mouse models, 736
 nociception channels, 736–737
 sensitization, 731–735
- Varenicline
 nicotine dependence and withdrawal therapy, 548
- Variable numbers of tandem repeats (VNTR)
 obsessive-compulsive disorders
 dopamine genetics, 223
- Velocardiofacial syndrome gene
 schizophrenia
 chromosome mapping, 346
 COMT catabolism and, 329
- Venlafaxine
 anxiety disorder therapy, 69
 obsessive-compulsive disorder therapy, 234
- Ventral hippocampal lesions
 in schizophrenia
 animal models, 265
- Ventral pallidum
 alcohol abuse studies, 476–480
 dopaminergic regulation hypotheses, 478–480
 GABA_{A1} subunit probe selectivity, 501–503
 GABAergic modification of dopamine agonists, 497–498
- Ventral tegmental area (VTA)
 alcohol abuse studies
 dopaminergic receptor systems and substrates, 472–473
 alcohol abuse studies in alcohol-preferring rats
 control substrates in, 470
 atypical antipsychotic drug mechanisms in
 clozapine D₂ receptors, 414–415
 cannabinoid receptors in, 675–676
 integrated glutamate/dopamine
 hypotheses of schizophrenia, 375–376
 nicotine dependence and withdrawal
 nicotine reinforcement substrates, 538–540
 withdrawal substrates, 542–543
 psychostimulant abuse
 monoamine neuropharmacology, 571–575
 neuropeptide pharmacology, 578–579
- Vesicular glutamate transporter
 glutamate theory of schizophrenia
 pathological evidence, 292
- Vesicular monoamine transporter (VMAT)
 protein
 dopamine hypothesis of schizophrenia, 284–285
- Visual system
 γ -hydroxybutyric acid (GHB) effects, 634
- Vitamin D receptor (VDR)
 anxiety neurobiology and, 32
- Vogel conflict test
 mouse models of anxiety
 neurosteroid effects, 145–146
- Vogel punished drinking test
 emotionality studies in mice, 8–9
- WAY-100635 compound
 5-HT_{2A}-5-HT_{2C} receptor interactions, 422–424
 nicotine dependence and withdrawal
 withdrawal substrate specificity, 542–543
- WIN 55,212-2
 analgesic properties, 666–668
 convulsant effects of, 673
 pain management and, 667–668
- Wisconsin card sort task (WCST)
 schizophrenia dopamine hypothesis
 genetic evidence, 286–287
- Withdrawal syndrome
 benzodiazepines, 74
 nicotine dependence and withdrawal
 withdrawal neurosubstrates, 541–543
 opiate addiction and, 699
- ZDHHC8 candidate gene
 schizophrenia molecular genetics, 330
- Ziprasidone
 schizophrenia therapy
 safety and tolerability, 389
- Zolpidem
 alcohol abuse studies
 GABA_{A1} receptor subunit selectivity, 499